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Abstract
MiRNAs are key cellular regulators and their dysregulation is associated with
many human diseases. The development of miRNA inhibitors has significant
implications for the therapy of diseases associated with aberrant miRNA
expression. It also provides chemical tools for studying miRNA function. This
dissertation focuses on the development of small-molecule based miRNA
inhibitors targeting miRNA biogenesis.
The dissertation consists of four chapters. In Chapter 1, the biogenesis of
miRNA was first introduced, followed by the explanation of miRNA function in
health and disease. Then the approaches used for regulating miRNA were
reviewed. Finally, the difficulties with miRNA regulation were summarized.
One of the key reactions in miRNA biogenesis is the processing of pre-miRNA
by Dicer enzyme. In Chapter 2, we developed a general strategy for inhibiting
miRNA biogenesis with bifunctional small molecules. By linking a pre-miRNA
binder and a weak Dicer inhibiting unit, we obtained bifunctional conjugates that
are able to block the Dicer processing of pre-miRNA and inhibit miRNA

v

production. This approach is expected to be applicable in generating more
inhibitors for other miRNAs.
MiRNAs are usually produced locally in a spatiotemporally controlled manner
to regulate gene expression. Thus, developing chemical tools for manipulating
miRNA with spatiotemporal preciseness is critical for studying miRNA. In Chapter
3, we expanded the application of the strategy described in Chapter 2 in
generating light controllable miRNA inhibitors. By conjugating the two functional
units with a photocleavable linker, we made a new bifunctional miRNA inhibitor.
Taking advantage of the photocleavage property of the linker, the bifunctional
inhibitor can be fragmented into separate non-inhibiting units and therefore be
deactivated by light. We expect that this strategy could be applied to generate
chemical biological tools that allow light-mediated spatiotemporal control of
miRNA maturation and contribute to the study of miRNA function.
In Chapter 4, we investigated the potential of targeting miRNA with
macrocyclic

peptidomimetics.

By

screening

a

combinatory

library

of

peptidomimetics against pre-miR-155, we identified a pre-miR-155 binder that is
able to block the Dicer processing, thereby reduce oncogenic miR-155 level and
induce apoptosis in cancer cells. This compound could be used as a lead for
generating more potent miR-155 inhibitors. The results of this investigation also
demonstrate that macrocyclic peptidomimetics could serve as new small
molecule scaffolds for RNA targeting.
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Chapter 1 Introduction
MicroRNAs (miRNAs) are a class of genome-encoded, short (~22 nucleotides),
single stranded, and non-coding RNAs. They regulate gene expression posttranscriptionally by targeting mRNA for translational repression or destabilization.
A wide range of biological processes are under the control of miRNAs, including
metabolism, proliferation, development, differentiation, apoptosis, et al.1-6
Increasing evidence shows that dysregulation of individual or multiple miRNAs is
associated with many human diseases, including cancer, viral infections, central
nervous system disorders, metabolic and cardiovascular diseases.2,

7-10

Thus,

miRNAs are considered a novel type of therapeutic target. In this chapter, the
biogenesis and function of miRNAs will be first introduced, followed by a
discussion of roles played by miRNAs in diseases. Then the approaches
currently used for miRNA regulation will be reviewed. Finally, an outlook on
future directions will be provided.
1.1 Biogenesis of miRNA
Since the discovery of the first miRNA gene, lin-4,11, 12 over 28,000 miRNAs
have been found in animals, plants and viruses.13 They are either independently
transcribed from miRNA genes or produced from other transcripts, including
introns of protein-coding genes, introns and exons of long non-coding RNAs.14
The long primary transcript (pri-miRNA) of miRNA genes is transcribed by RNA
polymerase II (Figure 1.1). The 5' end is capped by 7‐methylguanosine (m7Gppp)
and the 3' end is polyadenylated. Pri-miRNA is then processed into pre-miRNA
by the RNase III enzyme Drosha in the nucleus (Figure 1.1).5 Pre-miRNA is a

1

Figure 1.1 An illustration of the miRNA biogenesis pathway. In the standard
miRNA biogenesis pathway, the pri-miRNA, which is transcribed by RNA
polymerase II (Pol II), begins with a 7-methylguanosine cap (m7Gppp) and ends
2

with a 3′ poly(A) tail. The pri-miRNA contains a stem–loop structure that is
cleaved in the nucleus by the endonuclease Drosha. The resulting pre-miRNA is
exported from the nucleus by exportin 5 and then further cleaved by the
endonuclease Dicer to liberate a miRNA–miRNA* duplex, which is loaded into an
AGO protein. Subsequent maturation steps expel the miRNA*, producing a
mature miRNA-induced silencing complex (miRISC). Alternative pathways
typically replace individual steps of miRNA precursor processing. Adapted by
permission from Springer Customer Service Centre GmbH,5 COPYRIGHT
(2014).. 1
~60 nucleotide stem-loop structure. It can be recognized by nuclear transport
receptor exportin 5, and exported to the cytoplasm through the nuclear pore. In
the cytoplasm, another RNase III enzyme, Dicer, cleaves pre-miRNA to liberate a
~22 nucleotide miRNA-miRNA* duplex. The duplex is then loaded into an
Argonaute (AGO) protein and rapidly unwound. The mature miRNA is retained in
the AGO protein to form a miRNA induced silencing complex (miRISC), and the
complementary strand, miRNA star (miRNA*), is released.5, 15
1.2 Function of miRNA
The function of miRNA in miRISC is to guide the AGO protein to the
complementary target mRNA sequence and promote its translational repression,
deadenylation or degradation. The key determinant for miRNA target recognition
is a short sequence at the 5' end of miRNA, called the seed region (mainly
nucleotides 2 to 8).5 The recognition is based on Watson-Crick pairing of the
seed region to the match site (seed match) of the target mRNA. The seed match
can be in any region of an mRNA, but it is usually more likely to repress the
mRNA translation when the match site is in 3' UTR of the target. More than 60%
of all mammalian protein coding-genes are regulated by miRNAs.16 In addition to
translational repression, miRNAs have also been found to activate target
3

mRNAs17,

18

or act as molecular decoys that interfere with the function of

regulatory proteins.19 A recent study also showed that miRNA is capable of
binding to cell surface receptors, thereby functioning as ligand for signal
transduction.20
Through the regulation of target genes, miRNAs play important roles in diverse
biological processes. Animals with defects in miRNA expression fail to survive or
reproduce normally.8,

21, 22

Cell differentiation is regulated by miRNAs.23,

24

Depending on the cell type and environment, miRNAs can either inhibit or
promote stem cell renewal.23 A family of miRNAs from the miR-290 cluster were
found to regulate the cell cycle of embryonic stem cells by targeting cell cycle
inhibitors, thus facilitating the G1-S phase transition and promoting rapid
proliferation.25 MiR-125b was found to target multiple key proteins regulating
hematopoietic proliferation, innate immunity, inflammation and apoptosis.26
MiRNA-21 is another example of on miRNA that regulates apoptosis. One of its
target proteins is programmed cell death protein 4 (PDCD4). Knockdown of miR21 induces upregulation of PDCD4 and activates apoptotic pathways.27,

28

MiRNAs are also important for development. The first two miRNAs, lin-4 and let-7,
both control the timing of larva development in C. elegans.11, 29 The knockdown
of miR-124 in vertebrates was found to prevent neural development.30 The
development of heart, blood and vasculature is modulated by miRNAs as well.31,
32

In a mouse model, miR-122 acts as a key regulator of cholesterol and fatty

acid metabolism,33 and miR-33 was found to control cholesterol homeostasis,34
implying a role of miRNAs in regulating metabolism. The function of miRNAs in
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the immune system is also well documented.26, 35, 36 All of these findings have
unequivocally established the important roles of miRNAs in various biological
processes.
1.3 MiRNA dysregulation in disease
1.3.1 Cancer
The first evidence suggesting a role for miRNAs in cancer was reported in
2002.37 Calin et al. found that miR-15 and miR-16 genes were deleted or
downregulated in more than 60% of human chronic lymphocytic leukemias (CLL).
Both miR-15 and miR-16 genes are located in a chromosomal region that is
frequently deleted in CLL. Later, the same group found that a significant
percentage of miRNA genes are located in the same region,38 suggesting that
miRNAs are genetically associated with cancer. MiR-15 and miR-16 were later
found to induce apoptosis by targeting BCL2 mRNA.39 In 2005, let-7 was found to
regulate the expression of oncogenic RAS. The decreased expression of let-7 in
lung cancer correlates with increased RAS protein level.40 These findings clearly
show that miRNAs can act as tumor suppressors in cancer. The role of miRNAs
as

oncogenes

(oncomiRs)

came

to

light

in

a

study

showing

that

lymphomagenesis can be accelerated by overexpressing the miR-17-22
cluster.41 Soon afterwards, it was found that a single miRNA is sufficient to
induce tumor development.42, 43 To date, almost all types of cancer have been
found to be associated with altered miRNA expression.44 MiRNA deregulation in
cancer can be caused by different mechanisms, including chromosomal
abnormality, genomic mutation, epigenetic changes and alteration in miRNA
5

biogenesis.6, 44 Different tumors share some common characteristics of miRNA
deregulation, which creates opportunities for cancer treatment by miRNA
regulation.6, 15
1.3.2 Cardiovascular Disease
Cardiovascular disease is one of the leading causes of morbidity and mortality
in industrialized countries.45 Numerous recent studies support the role of miRNA
in cardiovascular disease. MiR-1-1 and miR-1-2 are the first two miRNAs
discovered to be relevant to cardiovascular diseases.45 They are specifically
expressed in cardiac and skeletal muscle precursor cells. The overexpression of
miR-1 in developing heart was found to lead to a decreased pool of proliferating
ventricular cardiomyocytes.46 Together with miR-1, miR-133 was reported to
stimulate myoblast proliferation.47 These findings implied the possibility of
miRNAs being involved in cardiovascular disease. This assumption was later
verified by other research, in which more than 12 miRNAs were deregulated in
cardiac tissue in mouse in response to stimuli that induce pathological cardiac
remodeling. Cardiac overexpression of miR-195 caused pathological cardiac
growth and heart failure in transgenic mice.48 Some other miRNAs were also
found to be deregulated in cardiac hypertrophy, including oncomiR-21.49 All these
studies clearly demonstrate the involvement of miRNAs in cardiovascular
diseases.
1.3.3 Neurodegeneration
As discussed above, miRNAs play important role in neuronal development, so
it is not surprising that they participate in neurodegenerative diseases, such as
6

Alzheimer’s disease, Huntington’s disease and Parkinson’s disease. In 2007,
progressive neurodegeneration was observed in Purkinje cells in the absence of
Dicer, one of the key proteins for miRNA biogenesis.50 In the hippocampal region
of Alzheimer’s diseased brain, miR-9, miR-25b and miR-128 were found to be
upregulated, while miR-124a was found to be downregulated.51 An increasing
number of studies indicate that miRNAs are involved in neurodegenerative
diseases.
1.3.4 Other diseases
In addition to the diseases discussed above, the roles of miRNAs in many
other pathological processes have also been studied.6, 22, 44 For example, they
are associated with autoimmune diseases,52 diabetes,53 metabolic disorders34, 54
and infectious diseases.55, 56
1.4 miRNA regulation
As miRNAs are aberrantly expressed in many diseases, they are potential
novel therapeutic targets.15 For diseases associated with miRNA overexpression,
inhibiting their function or biogenesis could serve as miRNA regulation
approaches that might be potentially applied in disease therapy. These
approaches also provide tools for the study of miRNA function. To this end,
several methods have already been developed.
1.4.1 Genetic knockout
MiRNA biogenesis includes a series of enzyme catalyzed chemical reactions.
Genetically knockout of the key processing enzymes, such as Drosha, Dicer and
Ago, can stop the production of miRNAs.2, 21 This method was used in studying
7

the bio-pathway and function of miRNA in early research. To study the function of
individual miRNAs, generation of mice lacking a specific miRNA gene through
knock out has been used. For example, the function of let-7 in developmental
timing57 and miR-1 in muscle growth58 were both studied with this method.
1.4.2 MiRNA sponge
A miRNA sponge is a highly expressed transgene harboring multiple miRNA
target sequences to sequester miRNA. This strategy

can

be applied to

modulate miRNA activity for loss of function studies.15 It makes both transient
and long term inhibition possible. Virally delivered miRNA sponges have been
used to study miRNA function in mouse models.59
1.4.3 Antisense oligonucleotides
Another approach for miRNA loss of function study is to use antisense
oligonucleotides (ASO). By base pairing with the complementary sequence of
mature miRNA, ASO is able to sequester mature miRNA and block its interaction
with the target mRNA, thus resulting in an inhibition of the miRNA function.15 The
very first application of ASO was achieved by using antisense DNA in
Drosophila.60 But it was later proved to be not effective enough in other
organisms. This is probably due to the fact that the antisense DNA is subject to
degradation by nucleases even before it reaches the target region. Moreover, the
poor binding affinity and lack of cell membrane permeability also limit its
application in regulating miRNA.61
To overcome these problems, chemical modifications have been carried out,
including modifications to the sugar and internucleotide linkage backbone
8

Figure 1.2 (A) Structures of the most commonly used chemical modifications in
anti-miR oligonucleotides. Locked nucleic acid (LNA) is a bicyclic RNA analogue
in which the ribose is locked in a C3'-endo conformation by introduction of a 2'-O,
4'-C methylene bridge. The 2'-fluoro (2'-F), 2'-O-methoxyethyl (2'-MOE) and 2'-Omethyl (2'-O-Me) nucleotides are modified at the 2' position of the ribose moiety,
whereas a six-membered morpholine ring replaces the sugar moiety in
morpholino oligomers. In the phosphorothioate (PS) linkage, sulfur replaces one
of the non-bridging oxygen atoms in the phosphate group. (B) Design of
chemically modified anti-miR oligonucleotides. (C) Schematic overview of the
miRNA inhibition approach using a fully complementary anti-miR and a seedtargeting tiny LNA. Adapted from reference.15. 2
(Figure 1.2 A). The 2'-fluoro (2'-F), 2'-O-methoxyethyl (2'-MOE) and 2'-O-methyl
(2'-O-Me) nucleotides are modified at the 2' position of the ribose moiety, while
locked nucleic acid (LNA) contains a 2'-O, 4'-C methylene bridge resulting in 3'endo conformation (Figure 1.2 A). All these modifications greatly improve the
binding affinity of ASO to the cognate miRNAs. LNA possess the highest affinity.
9

To improve the stability, the phosphodiester linkage can be modified into a
phosphorothioate (PS) linkage, in which one oxygen atom in the phosphate is
replaced with sulfur atom. The modification improves the nuclease resistance of
ASO significantly. Other modifications include the incorporation of a non-charged
morpholine ring (morpholino) or N-(2-aminoethyl)-glycine (PNA) into the
internucleotide linkage backbone. They are completely nuclease resistant. To
improve the cellular uptake efficiency, ASO can be conjugated to cell permeable
lipids (Figure 1.2 B). Cell penetrating peptides, nanoparticles and aptamers were
also reported to be able to deliver ASO.62-64 The seed targeting tiny 8-mer LNA
ASO (Figure 1.2 C) was found to be able to silence target miRNA in vivo without
additional conjugation.65 With these research progresses, ASO has made their
way into clinical trial.66, 67
Despite the great success in the design and application of chemically modified
ASOs, the in vivo delivery efficiency is still very low. With current technology,
most of the ASO delivered into cells are trapped inside the endosomes, only a
few are exported into the cytosol to scan for the target miRNA.68 Another
limitation for their use in vivo is the off target effects. The short ASO carries the
inherent risk of binding RNAs other than the intended miRNAs. Imperfect base
pairing could also contribute to off target binding. Thus, an understanding of the
off target effects resulting from undesired binding is important for the
development of ASO based therapeutics.15 ASO also suffers from poor
pharmacokinetic and bio-distribution profiles.69, 70
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1.4.4 Small molecule inhibitors
MiRNA biogenesis is a multiple-step enzyme catalyzed process, including
transcription, Drosha processing, Dicer processing and AGO loading. Small
molecules, capable of inhibiting any of these processes by binding the enzymes,
factors or RNA substrates, may serve as potential miRNA regulators.
1.4.4.1 Targeting miRNA transcription
One of the first studies on small-molecule inhibitors of the miRNA pathway
was reported by Deiters and co-workers.71 They designed constructs expressing
luciferase under the control of miRNA binding sequences in the 3'-untranslated
region (3'-UTR). These constructs served as sensors to detect the presence of
specific mature miRNAs. With this assay, they screened more than 1000
compounds and identified compound 1, which was further optimized to
compound 2, as an inhibitor of miR-21 production. Mechanistic studies showed
that compound 2 blocks the transcription of the miR-21 gene into pri-miR-21.

2

2

2

1

2

4

3
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A similar assay was used for screening inhibitors of miR-122,72 which is the
most abundant miRNA in liver and is involved in hepatocellular carcinoma
development and hepatitis C virus (HCV) infection. Compound 3 was identified to
inhibit miR-122 transcription and HCV replication in liver cells, representing a
new approach to the treatment of HCV infections. In addition, compound 4 was
found to activate pro-apoptotic miR-122 expression, leading to increased
caspase expression and reduced cell viability, having implications in cancer
therapy.72
1.4.4.2 Targeting Drosha/Dicer processing
RNA consists of different types of secondary structures, including duplex,
internal loop, bulge and hairpin loop. These structures can serve as binding
pockets for small molecules,73 which may disrupt the interaction between
targeted RNA and related protein, thus inducing the desired biological effects.
Many different types of RNA including rRNA, tRNA, mRNA, et al. have been
shown targetable by small molecules.73 Within pri-miRNA and pre-miRNA,
secondary structures play important roles for proper recognition and processing
by Drosha or Dicer. They provide great opportunity for identifying pri/pre-miRNA
binders, which could interrupt the Drosha/Dicer processing and serve as miRNA
inhibitors.61
1.4.4.2.1 Drosha inhibitor
Diaz et al. screened a library of 14,024 peptoids for pri-miR-21 binders.74
Compound 5 was identified to bind the apical loop of pri-miR-21. Further study

12

showed that it inhibits the cleavage of pri-miR-21 by Drosha with a clear
specificity over pri-miR-16.74
OH
O
N

HN

O
N

N

O

O

NH2

N
O

N
H2N

NH
NH2
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The Disney group developed a rational design approach, named Inforna, to
target miRNAs in a transcriptome-wide and target agnostic manner.75 They first
designed a two dimensional combinatorial screening (2-DCS) strategy, in which a
library of random RNA secondary structures is titrated against a small molecule
microarray.76 The subsequent RNA sequencing reveals the RNA motifs that bind
small molecules. The data is then subject to a statistical approach, called
Structure-Activity Relationships Through Sequencing (StARTS), which predicts
the fitness of RNA motif and small molecule interaction based on affinity and
selectivity.77 The information is then cross referenced to the motifs found in
pri/pre-miRNAs as reported in miRBase,13 thereby identifying the ideal RNA
target for a given small molecule.
Using this approach, compound 6a was identified to be an effective inhibitor for
miR-10b.78 It increases the amount of pri-miR-10b while decreasing the amount
of precursor and mature miR-10b in cells, suggesting an inhibition of Drosha
processing. Recently, they found that compound 6b inhibits the Drosha
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processing of pri-miR-525.79 Compound 7 was identified as a Drosha site
inhibitor for miR-96. It increases the level of pri-miR-96 while reducing those of
pre- and mature miR-96 in cells. Further study showed that compound 7 is even
more selective than a LNA oligonucleotide that is complementary to the seed
region of miR-96.75
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1.4.4.2.2 Dicer inhibitor
Inforna can also be used to identify Dicer processing inhibitors. Compound 8 is
one example. The Disney group found that it impedes the biogenesis of miR-544
by inhibiting the Dicer processing. They also probed the role of miR-544 using
compound 8. It turns out that inhibition of miR-544 biogenesis disrupts adaptive
responses to hypoxia by modulating ATM-mTOR signaling.80

Aminoglycosides are a category of widely used anti-bacterial agents. They
disrupt protein elongation by targeting the 30S ribosomal subunit.81 Because of
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their great affinity to RNA, they are frequently used for probing various RNA
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The Maiti group first reported the study of aminoglycosides in

miRNA inhibition.85 They screened a library of aminoglycosides in cells
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expressing luciferase under the control of miR-21 target sequence within the 3'
UTR. Streptomycin, which is used as a tuberculosis drug, was found to decrease
the expression of luciferase. In vitro assays showed that it was able to block
Dicer cleavage of pre-miR-21 significantly and induce downstream effects. In
another study, several aminoglycosides (including neomycin and kanamycin)
were found to bind pre-miR-155 but not inhibit the Dicer cleavage in vitro.86
Meanwhile, the Duca group found that neomycin was able to inhibit Dicer
cleavage of several other miRNAs in vitro, including pre-miR-17, pre-miR-21,
pre-miR-372 and pre-miR-373.87 The Maiti group also reported that neomycin
inhibits the biogenesis of pre-miR-27 in MCF-7 breast cancer cells.88 These
results showed the possibility of using aminoglycosides as leads for generating
miRNA inhibitors.
Therefore,

rationally

designed

modification

of

RNA

binders,

like

aminoglycosides, emerges as a new way for targeting pre-miRNAs. To improve
the cell permeability, affinity and selectivity of neomycin toward pre-miRNAs,
Maiti et al. designed a synergistic approach in which a bisbenzimidazole moiety
was linked to neomycin, a pre-miR-27 binder.89 The bisbenzimidazole scaffold is
cell permeable and also known to bind various RNA structures. The dual binding
conjugate 9 was found to penetrate easily into cells and inhibit miR-27 production
significantly. Similarly, the Duca group conjugated artificial nucleobases to
neomycin. They found that the incorporation of the nucleobases increased the
binding affinity and selectivity of the conjugate 10 towards miR-372 and miR373.90 To improve the binding affinity of 11 to the cytosine bulge in RNA duplexes,
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the Nakatani group designed an expanded three ring system (12), which
improved the stacking interaction with neighboring base pairs in RNA duplex.91
12 shows strong binding affinity to pre-miR-29a and inhibits miR-29a maturation
in vitro.
In an effort to search for new RNA binding scaffolds, Schneekloth and
coworkers screened a microarray based small molecule library for new motifs
binding to pre-miR-21. Hit compounds 13 and 14 were found to bind to pre-miR21 and disrupt the processing by Dicer.

Peptides serve as an important source for discovering small molecules
targeting various biological molecules. To discover peptides targeting pre-miR155, the Shin group performed microarray based screening.92 A few peptides
were identified to bind pre-miR-155, inhibit miR-155 production and induce
cancer cell apoptosis. By using electrophoresis mobility shift assay, the Varani
group

screened

a

library

of

cyclic

peptides

for

binding

pre-miR-21.

Cyclo(RVRTRGKRRIRRpP) was found to bind to the pre-miR-21 hairpin with an
apparent Kd of 200 nM. It is also active in blocking pre-miR-21 processing in vitro
and in cells. Phage display technology has been widely used for studying proteinprotein, protein-peptide, protein-DNA and protein-RNA interactions.93, 94 Recently,
the Maiti group used this technology to discover peptides that bind pre-miR-21 by
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screening a peptide library of around 109 or more complexity.95 One peptide,
ALWPPNLHAWVP,

was

identified

to

selectively

downregulate

miR-21

expression in cells by blocking Dicer processing. They also found that this
peptide inhibitor induces apoptosis and suppresses cell invasion and migration.
The results of these studies demonstrate the potential of targeting pre-miRNAs
with peptides.

Computer-aided drug discovery or design methods have played a major role in
the development of therapeutically important small molecules for over three
decades.96 Shi et al. first used high-throughput docking to screen for ligands that
target miR-21. Compound 15 was identified to bind the Dicer site of pre-miR-21.
In cell assays showed that 15 inhibits the biogenesis of miR-21 in a dosedependent manner, resulting in suppression of tumor growth and progression.97
1.4.4.3 Targeting AGO loading
Another approach used for the inhibition of miRNA function is to block the
loading of mature miRNA onto the AGO2 protein, thus preventing the formation
of miRISC complex. In a cell based generic screening, Watashi et al. found that
trypaflavine (16) interrupts the miRNA pathway by blocking the AGO2 loading
process.98 Tan et al. developed an assay for large scale screening of
miRNA/RISC loading modulators. The assay is based on the fluorescence
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polarization of TAMRA-labeled RNAs loaded onto AGO2. Using this method they
identified compound 17, 18 and 19 as RISC loading inhibitors.99

1.4.4.4 Other inhibitors
The Deiters group recently screened a library of more than 300,000
compounds for miR-21 inhibitors with a luciferase-based reporter assay.100 A set
of aryl amide small-molecule inhibitors were identified to inhibit miR-21
specifically. Estradiol was also reported to downregulate miR-21 expression and
increase miR-21 target expression in MCF-7 cells.101 However, the inhibition
modes of both remain unclear.
1.5 Summary and outlook
When the first small non-coding RNA was identified two decades ago, the
existence of miRNAs was completely unknown, not to mention the importance.
Since then, our knowledge of miRNAs has grown exponentially. A great amount
of success has been achieved in disclosing the mechanism of the miRNA bio19

pathway. Efforts for exploring the detailed role of miRNA in various biological
activities and developing miRNA as a new therapeutic target are still desired.
This research field will benefit from the development of miRNA regulators.
Although it is extremely difficult to target RNA,73 promising progress has been
achieved in miRNA regulation. ASO based miRNA inhibition has recently made
its way to clinical trials, despite the constraints of delivery, pharmacokinetics,
pharmacodynamics and off-target effects. Within a very short time span, many
small-molecule based miRNA inhibitors have been reported for targeting different
processes of the miRNA biogenesis pathway, especially pre-miRNA processing
by Dicer. However, challenges remain for small-molecule based miRNA inhibition.
Some pri/pre-miRNA binders identified from affinity based screening were not
active in blocking Drosha/Dicer processing due to different reasons. Rational
designed modification of those pre-miRNA binders may create new opportunities
for regulating miRNA. Moreover, the understanding of pri/pre-miRNA motifs that
are targetable is very poor so far, and the knowledge of chemical structures with
high binding affinity to pri/pre-miRNAs is also very limited. Finally, the diversity of
the currently used RNA targeting scaffolds is very low. Most of them are
polycationic compounds, such as aminoglycosides and multiply charged peptides.
They usually suffer from poor selectivity and cell permeability. Thus, the
development of novel RNA targeting scaffolds with good cellular uptake
efficiency and specificity is highly desired.
In this dissertation, a general strategy was first developed for inhibiting miRNA
biogenesis with bifunctional small molecules made from pre-miRNA binder
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(Chapter 2). The potential of using this strategy for spatiotemporal miRNA
regulation was also studied (Chapter 3). Finally, a novel type of miRNA targeting
scaffold was developed (Chapter 4). The results of these studies have significant
implications for not only the therapy of diseases associated with miRNA
dysregulation, but also the study of miRNA function.
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Chapter 2 Regulating miRNA Biogenesis by Bifunctional Small Molecules
Adapted with permission from J. Am. Chem. Soc., 2017, 139 (14), 4987–4990.
Copyright © 2017, American Chemical Society
2.1 Introduction
One common way used for developing miRNA inhibitors is to screen chemical
libraries against pre-miRNAs. The hits are expected to bind pre-miRNAs and
disrupt the interactions between pre-miRNAs and Dicer, thus inhibiting miRNA
maturation. However, it is not uncommon that small molecules, which are
selected using binding-based screening against miRNA precursors, are unable to
block miRNA maturation.86,

87

This phenomenon might be a consequence of

promiscuous targeting and/or poor cell permeability of these small molecules. In
addition, these small molecules might possess binding affinities that are
insufficiently low to compete with the extensive macromolecule interactions
occurring between RNAs and other binding partners. To enhance binding
between small molecules and targeted miRNA precursors, rationally designed
bifunctional molecules have been developed in which additional binding moieties
are conjugated to the original RNA-recognizing molecules. For example, Duca
and co-workers designed neomycin-nucleobase conjugates that have additional
base pairing driven affinities against pre-miRNAs to give new inhibitors that block
maturation of miR-372 and -373.90,

102

Maiti and co-workers developed dual

binding neomycin-bisbenzimidazole conjugates, which contain an intercalating
unit to enhance binding of neomycin, and showed that the conjugates serve as
inhibitors for oncogenic miR-27a.89
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Figure 2.1 A schematic illustration of the new approach to regulate miRNA
biogenesis by using bi-functional small molecules that target pre-miRNA. . 3
In this chapter, we devised and tested a new strategy to regulate miRNA
biogenesis that relies on the use of newly designed bifunctional small molecules
(Figure 2.1). The purpose of previously developed bifunctional molecules is to
target two closely located binding sites and utilize bi-valent recognition to
enhance binding affinity. In contrast, our bifunctional molecules are designed to
deliver a specific Dicer inhibitor to the Dicer-catalyzed cleavage site in the target
pre-miRNA/Dicer complex. The new conjugates consist of a high affinity premiRNA binding unit linked to a low affinity Dicer inhibition unit. The Dicer inhibitor
in the conjugate is selected so that it alone does not inhibit Dicer to a significant
extent. As a result, the pan-cellular function of Dicer will not be disrupted by the
bifunctional molecule. However, recognition of a target pre-miRNA by the RNA
binding unit in the conjugate brings the Dicer inhibitor unit into close proximity
with the pre-miRNA cleavage site of bound Dicer, thus causing blockage of the
activity of Dicer. Importantly, by functioning in this manner, the inhibition unit will
promote inhibition of the production of the target miRNA.
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Oncogenic miR-21 is upregulated in many cancers.49 As a result, small
molecules that inhibit the production of miR-21 can serve as useful tools to study
the roles played by miR-21 in cancers and as potential cancer therapeutic agents.
To demonstrate the feasibility of the new strategy described above, we designed,
prepared and tested bifunctional inhibitors that block the biogenesis of human
miR-21.
2.2 Results and discussion
2.2.1 Identification of pre-miR-21 binder
The first stage of assembling the newly designed bifunctional miR-21 inhibitors
involves identification of a pre-miR-21 targeting small molecule. Fluorescence
polarization (FP), a powerful tool for studying molecular interactions, was utilized
for this purpose.103, 104 In this assay, the degree of FP from a fluorophore-labeled
small molecule increases when it forms a complex with a macromolecule owing
to a reduction in the rate of fluorophore tumbling.
To identify small molecules that bind pre-miR-21, we used the FP-based
competitive binding assay to screen ligands that can compete with a moderate
affinity ligand for binding to pre-miR-21. Because kanamycin (Figure 2.2) binds to
several RNAs,73, 83, 105, 106 we expected that it would bind pre-miR-21 and, as a
result, serve as the standard ligand in the FP-based screening protocol. To verify
this assumption, kanamycin derivatives, containing a 1,8-naphthalimide
fluorophore at either the primary hydroxyl (KOF) or the primary amine group
(KNF) were prepared (Figure 2.2). The binding affinity of KOF and KNF to pre-
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Figure 2.2 (a) Synthesis of kanamycin building blocks. (b) Synthesis of KOF and
KNF. Reagents and conditions: (a) DCC, HOSu, DCM; (b) DCC, endo-Nhydroxy-5-norbornene-2,3-dicarboximide, DCM; (c) Boc2O, TEA, DMF/H2O, 60 ;
(d) 2,4,6-Triisopropylbenzenesulfonyl chloride, pyridine, R.T., 16 h; (e)
Cysteamine hydrochloride, Cs2CO3, DMF, 16 h; (f) Compound 20, TEA, DCM; (g)
Compound 21, H2O/acetone; (h) Boc2O, H2O/acetone; (i) H2, Pd/C, MeOH; (j) nButylamine, EtOH, reflux; (k) Ethylenediamine, dioxane, reflux; (l) 6Azidohexanoic, EDCI, HOBt, DMF; (m) i) CuSO4, Sodium ascorbate, DMSO/H2O;
ii) TFA, DCM.. 4
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miR-21 was determined using the FP assay. Based on the saturation binding
curve of KOF versus pre-miR-21 from the FP assay, a binding affinity (Kd) of 419
± 83 nM was obtained (Figure 2.3 a). On the other hand, the binding affinity of
KNF to pre-miR-21 was found to be too small to be determined (Figure 2.3 b).
Based on these results, KOF was employed as the standard pre-miR-21 binding
ligand in the FP-based screening protocol.

Figure 2.3 Fluorescence polarization of KOF (a) and KNF (b) in the presence of
different concentrations of pre-miR-21. The results were the average from 3
independent experiments. The error bars represent the standard error of mean
(N = 3). 5
Screening was carried out by incubating the pre-formed KOF/pre-miR-21
complex with 13 commercially available aminoglycosides, which are one of the
best studied classes of molecules that target RNAs.73, 83, 103-107 Displacement of
KOF from pre-miR-21 by an aminoglycoside with higher affinity against pre-miR21 is reflected in a decrease of the FP value. Among the tested substances,
neomycin was found to reduce the FP of KOF/pre-miR-21 to a value that
matches that of free KOF, indicating a complete displacement (Figure 2.4).
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Figure 2.4 Fluorescence polarization of KOF in the absence or presence of premiR-21 and different aminoglycosides. The error bars represent the standard
error of the mean (N = 3). 6

Figure 2.5 Synthesis of neomycin building blocks (A) and NF (B). Reagents and
conditions: (a) Boc2O, TEA, DMF/H2O, 60 ; (b) 2,4,6-Triisopropylbenzenesulfonyl chloride, pyridine, R.T., 16 h; (c) Cysteamine hydrochloride, Cs2CO3,
DMF, 16 h; (d) 6-Azidohexanoic, EDCI, DIPEA, DCM; (e) 6-hexynoic, EDCI,
DIPEA, DCM; (f) i) CuSO4, Sodium ascorbate, DMSO/H2O; ii) TFA, DCM.. 7
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To validate the binding of neomycin to pre-miR-21, the hydroxyl fluorophoretagged derivative of neomycin, NF, was prepared (Figure 2.5). Employing the
reported method,103, 104 the amino groups in neomycin were protected and the
primary hydroxyl group was tranformed to an amino group to give 35. Reaction of
35 with 6-hexynoic gave the alkyne 37, which was later coupled with 32. The
subsequent deprotection of the amino groups produced NF.

Figure 2.6 Fluorescence polarization of NF in the presence of different
concentrations of pre-miR-21. The error bars represent the standard error of the
mean (N = 3).. 8
Using the FP assay, we determined that the Kd of NF to pre-miR-21 is 38 ± 2
nM (Figure 2.6), which is 10 fold smaller than that of KOF. This result confirms
that neomycin strongly binds to pre-miR-21 and led to the selection of neomycin
as the pre-miR-21 binding unit in the new bifunctional molecules. Importantly, the
above result indicates that modification of the primary hydroxyl group on
neomycin does not disrupt the binding, therefore, this hydroxyl group can be a
suitable position to conjugate the Dicer inhibition unit.
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2.2.2 Selection of Dicer inhibitor
The active site of Dicer is located within the RNase III domain, which cleaves
pre-miRNAs through a mechanism in which two metal ions (Mg2+) catalyze the
phosphoryl transfer reaction.108 The distance between the two Mg2+ is around 4 Å,
similar to those in active sites of other mechanistically similar RNases. Many
RNase inhibitors with metal chelating properties have been developed,109,

110

including the N-hydroxyimide 38 that inhibits influenza endo-nuclease at
micomolar concentrations.110 As a result, 38 was used as the Dicer inhibiting unit
in the new bifunctional molecules.

2.2.3 Synthesis of bifunctional small molecules
The route to synthesize bifunctional inhibitors began with preparation of a
series of homophthalic acids (42A-D) possessing alkynyl polyethylene glycol tails
of different lengths (Figure 2.7). Reactions of 42A-D with para-methoxybenzyl
(PMB) oxyamine produced O-PMB-oxyimides 43A-D that were later coupled to
neomycin. The free imide 44, used as a control in activity assays, was produced
by removing the PMB group in 43A with trifloroacetic acid. An azide modified
neomycin derivative 36 was synthesized as shown in Figure 2.5. 36 and 43A-D
were then coupled using click chemistry. Subsequent removal of the Boc and
PMB protecting groups from the click products by using trifloroacetic acid
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generated bifunctional molecules 45A-D containing tethers of different length
linking the two functional units.

Figure 2.7 Synthesis of bifunctional inhibitors. Reagents and conditions: (a)
H2SO4, MeOH, reflux; (b) Propargyl bromide, K2CO3, DMF; (c) DIAD, Ph3P, THF;
(d) i) LiOH, MeOH/H2O; ii) HCl; (e) O-(4-Methoxybenzyl)-hydroxylamine, toluene,
reflux; (f) TFA, DCM; (g) i) CuSO4, Sodium ascorbate, DMSO/H2O; ii) TFA, DCM.
9

2.2.4 In vitro Dicer blocking activity
The ability of 45A-D to inhibit Dicer-mediated pre-miR-21 cleavage in vitro was
determined (Credit to Umesh Bhattarai). For this purpose,
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P-labeled pre-miR-

21 was prepared by in vitro transcription,111 and then incubated (37 °C, 2.5 h)
with recombinant human Dicer in the absence or presence of 45A-D, or one of
the following, the Dicer inhibition unit alone (i.e. compound 44), the pre-miR-21
binding unit alone (i.e., neomycin), or a commercial morpholino-based anti-miR21 ASO designed to block miR-21 maturation (anti-miR-21 A). The extent of
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cleavage of pre-miR-21 (72 nt) into mature miR-21 (22 nt) was then determined
u
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i

z
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a

Figure 2.8 (a) The representative image of the electrophoresis analysis of Dicermediated pre-miR-21 cleavage in the presence of tested compounds. (b)
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Densitometric quantitative analysis of miR-21 levels from three independent
assays as in (a). The error bars represent the standard error of mean (N = 3). (c,
d & e) Dose dependent inhibition of Dicer by different compounds. Figure
courtesy of Umesh Bhattarai.. 10
15% denaturing polyacrylamide gel and phosphor-imaging. As shown in Figure
2.8 a, Dicer cleaves pre-miR-21 completely to form mature miR-21. In addition,
anti-miR-21 A, as a positive control, inhibits cleavage by 70% at 5 μM, indicating
that the assay performs correctly. Importantly, bifunctional molecule 45A inhibits
Dicer promoted cleavage in a dose dependent manner, reducing the level of
miR-21 formation by 90% at 5 μM (Figure 2.8 a-c). A comparison of the results
coming from studies with 45A-D shows that Dicer catalyzed miR-21 formation
increases as the length of the linker between the two functional units increases,
demonstrating that the inhibitory activity is critically altered by the distance
between the two functional units. In contrast to the bifunctional molecules,
unmodified neomycin, at concentrations up to 1 mM, does not inhibit Dicer
activity (Figure 2.8 a & d). Furthermore, the inhibitor unit alone (i.e., 44) displays
no inhibition at concentrations up to 50 μM (Figure 2.8 a & e). The combined
results clearly show that conjugation of neomycin, the pre-miR-21 recognition
unit, to the Dicer inhibitory unit 38 significantly enhances the Dicer inhibition
potency (>200 fold comparing 45A to neomycin) and that the presence of a linker
of proper length between the two units is essential for the activity.
2.2.5 MiRNA inhibition activity in cell
Because 45A is the most potent Dicer inhibitor in the in vitro assay, it was
used for in cell investigations. To study the in cell inhibitory activity of 45A,
mature miR-21 expression levels were determined by utilizing the RT-qPCR
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assay. HEK293T cells were transfected with pCMV-miR21 plasmid expressing
pre-miR-21 and treated at the time of transfection with neomycin, a commericial
phosphorothioate-based

anti-miR-21

ASO

(anti-miR-21

B),

or

various

concentrations of 45A. As shown in Figure 2.9, 45A inhibits the expression of
miR-21 in a dose-dependent manner (76% reduction at 5 μM when compared to
non-treated cells). The activity of 45A is similar to that of anti-miR-21 B. In
contrast, neomycin does not cause a significant decrease in miR-21 level at 100
μM. When 45A was added 4 h after transfection, no inhibititory activtiy was
observed, which suggests the transfection procedure may assist cellular delivery
of 45A.

Figure 2.9 RT-qPCR analyses of mature miR-21 expression levels in HEK293T
cells. The error bars represent the standard error of the mean (N = 3).. 11
2.2.6 Downstream effect of miR-21 inhibition by 45A
Programmed cell death protein 4 (PDCD4) is a tumor suppressor protein,
whose mRNA is a direct target of miR-21.112 Expression of miR-21 represses
33

PDCD4 expression in HEK293T cells and repression of miR-21 should derepress PDCD4 production. As expected, the expression level of PDCD4 protein,
determined by using western blotting and compared to non-treated cells,
increases by 90% when cells are treated with 45A (Figure 2.10). The cellular
assay results demonstrate that 45A is highly active in repressing miR-21
formation in cells.

Figure 2.10 (a) The representative image of western blotting analysis of PDCD4
levels in pre-miR-21 expressing HEK293T cells with or without 45A treatment. (b)
Densitometric quantitative analysis of PDCD4 levels from three independent
assays as in (b). The error bars represent the standard error of the mean (N = 3)..
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2.2.7 Selectivity of bifunctional molecule
In the design of bi-functional molecules employed in this study, we utilized
aminoglycosides as the pre-miRNA binding unit because they are well-known
RNA binders. However, aminoglycosides, including neomycin, are known to
target a number of RNA sequences and, as a result, the new bifunctional
substances could suffer from selectivity issues.73, 83, 89, 90, 102-107
To investigate the miRNA regulation selectivity of the neomycin-based bifunctional molecule 45A, its ability to inhibit another randomly chosen miRNA,
miR-34a, in HEK293T cells was determined using RT-qPCR. The results show
that 45A indeed reduces the production of miR-34a (40% reduction at 5 μM when
34

compared to non-treated cells), but not at the same level of potency as it does
against miR-21 at the same concentration (Figure 2.11). Thus, although 45A
displays some degree of selectivity, the incorporation of more selective premiRNA recognition moieties other than aminoglycosides in the bifunctional
design may lead to improved RNA selectivity.

Figure 2.11 RT-qPCR analysis of mature miR-21 and miR-34a expression level
in HEK293T cells expressing corresponding pre-miRNA with or without 45A
treatment. The results were the average from 3 independent experiments. The
error bars represent the standard errors of the mean (N = 3).. 13

Figure 2.12 The effects of 45A on the expression of an EGFP reporter plasmid in
HEK293T and CHO cells at 5 µM concentration for 24 h treatment. The results
were the average from 3 independent experiments. The error bars represent the
standard deviations (N = 3).. 14
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2.2.8 Effect of bifunctional molecule on translation
Because neomycin is known to target ribosomal RNA and interfere with
translation, effects of 45A on translation were tested by transfecting HEK293T
and CHO cells with an EGFP reporter followed by 45A treatment.75, 113, 114b No
significant change in EGFP expression was observed at the concentration that
inhibits miR-21 maturation (Figure 2.12), indicating that the bifunctional small
molecule does not interfere with the function of ribosomal RNA.

Figure 2.13 The cytotoxicity of 45A (5 µM) toward HEK293T and CHO cells was
evaluated by the MTT assay. (a) Cells were directly treated with 45A. (b) Cells
were transfected with an EGFP reporter plasmid and treated with 45A at the
same time. The cell viability percentages were calculated by comparing treated
cells to non-treated ones. The results were the average from 3 independent
experiments. The error bars represent the standard deviations (N = 3).. 15
2.2.9 Cytotoxicity of bifunctional molecule
The effect of 45A on the viability of HEK293T and CHO cells was also studied
by MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay. As
shown in Figure 2.13 a, no significant change in cell viability was observed when
cells were directly treated with 45A (5 µM). Considering the improved cellular
uptake of 45A by the transfection procedure (discussed in 2.2.5), we also tested
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the viability of cells transfected with the EGFP reporter plasmid and treated with
45A at the same time. Compared to the control without 45A treatment, cells
treated with 45A showed the same level of viability (Figure 2.13 b). These results
show that under the condition of miR-21 inhibition, 45A does not cause cell
toxicity.
2.3 Summary
In summary, a new approach to regulate miRNA maturation was developed
that relies on the use of a Dicer-inhibiting bifunctional small molecule. The study
showed that 45A, which contains neomycin as a pre-miR-21 binding unit and the
N-hydroxyimide 38 as the Dicer inhibitory unit, inhibits miR-21 maturation in vitro
and in cells. Together, these observations demonstrate that the new bifunctional
strategy is applicable to the design of active miR-21 inhibitors based on an
otherwise non-active pre-miR-21 binder. We expect that the strategy will be
affective in generating new bifunctional regulators for miRNAs.
2.4 Experimental section
2.4.1 In vitro Transcription of pre-miR-21
The pre-miR-21 RNA was in vitro transcribed111 from template oligonucleotides
using transcription kit (Ambion). Briefly, forward primer:
5'-GAAATTAATACGACTCACTATAGGTGTCGGGTAGCTTATCAGACTGATGTT
GACTGTTGAATCTCATGGC-3’
and reverse primer:
5'-TGTCAGACAGCCCATCGACTGGTGTTGCCATGAGATTCAACAGTCAAC-3’
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2 μM of each were subjected to primer extension using Taq polymerase per the
manufacture’s protocol. The hybrid template with T7 promoter was used for in
vitro transcription following manufacturer’s instructions (Ambion). Right before
use, the RNA prepared was refolded as follows: RNA was heated to 94 oC for 2
min and then cooled to 4 oC at a rate of 1 oC/s.
2.4.2 Fluorescence polarization binding assay
The affinity of fluorophore tagged aminoglycosides to pre-miR-21 was
determined following a literature method.103 30 nM of fluorophore tagged
aminoglycoside was incubated with various concentrations of pre-miR-21 (3 nM
to 4 µM) in cacodylate buffer (10 mM, pH 7.4, 0.01% Triton X-100) at room
temperature for 1 hour. The polarization values were obtained with a microplate
reader (SpectraMax i3X, Molecular Devices) equipped with a fluorescence
polarization detection cartridge. Polarization units (mP) were plotted against premiR-21 concentration and fit in the following equation to determine Kd:
P

P

∆P

RNA

F

RNA
2F

F

4 RNA

F

Where P0 is the polarization of free fluorescent small molecule, P is the
measured polarization at each pre-miR-21 concentration [RNA]total, ∆P is the total
change of polarization upon saturation, [F]total is the total concentration of
fluorescent compound. For the competition binding experiments, various
competitors (3 µM) were incubated with fluorophore tagged aminoglycosides (30
nM) and pre-miR-21 (1 µM) for 1 h before reading. The experiment was
performed in triplicate.
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2.4.3 Dicer-mediated pre-miRNA cleavage assay
The Dicer-mediated pre-miR-21 cleavage assay was performed at 37 °C for
2.5 h using Dicer buffer (Genlantis). Each reaction mixture contained 1 μL of

32

P

labeled pre-miR-21 (~20 ng, prepared by in vitro transcription), 0.5 unit of Dicer
(1 μL, Genlantis) and indicated compounds with a final volume of 10 μL. A
morpholino

anti-miR-21

nucleotide

(Anti-miR-21

A,

Sequence:

5’-

AGTCAACATCAGTCTGATAAGCTAC-3’) was used as a positive control. The
reaction was stopped by boiling with equal volume of 95% formamide with dyes
(Thermo Fisher Scientific) and then separated in 15% denaturing polyacrylamide
gel. The gel was imaged with phosphorimager and analyzed by Quantity one
software (Bio-rad).
2.4.4 Cell culture and transfection
pCMV-miR21 (Addgene plasmid # 20381) and MSCV-miR-34a (Addgene
plasmid # 63932) were obtained from Addgene. HEK293T and Chinese hamster
ovary (CHO) cells were cultured in DMEM medium (Gibco) without antibiotics,
supplemented with 10% FBS and 2 mM GlutaMAX (Life Technologies) at 37

in

a humidified atmosphere containing 5% CO2. HEK293T cells were plated 1 day
before transfection in 24-well plates at 2.0 × 105 cells/well. Transfections with
DNA plasmid mixtures were carried out at ~70% cell confluency using Lipo2000
transfection reagent (Invitrogen). Briefly, DNA 200 ng, Lipofectamine 2000
(Thermo Fisher Scientific) 1 µL and indicated amount of tested compounds were
incubated in Opti-MEM reduced serum medium (50 µL) at room temperature for
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5 min before transfection. A phosphorothioate-based anti-miR-21 ASO (Anti-miR21 B, Integrated DNA Technologies, Sequence: 5’-CAACATCAGTCTGATAAGC
TAC-3’) was used as a positive control. Cells were harvested for RNA extraction
after 22 h or for western blot analysis after 84 h.
2.4.5 RNA extraction and RT-qPCR
Total RNA was extracted using miRNeasy Mini Kit (Qiagen) per the
manufacturer’s protocol. Approximately 10 ng of total RNA was used in reverse
transcription reactions, which were completed using a Taqman MicroRNA RT Kit
(Applied Biosystems) per the manufacturer’s protocol. RT-qPCR was performed
on CFX96 Real Time PCR System (Bio-Rad) using Taqman Universal PCR
Master Mix (Applied Biosystems) with 1 µL of the RT product. All primer sets for
mature miRNAs were purchased from Applied Biosystems. The triplicate
threshold cycles (Ct) obtained for each treatment were used to determine the
relative levels of miRNA normalized to U6 small nuclear RNA using the 2-∆∆Ct
method.115 The result presented was based on three independent assays.
2.4.6 Western Blotting
Total protein was extracted using RIPA buffer and quantified using a Bio-Rad
Protein Assay. Approximately 20 μg of total protein was resolved on a 4-15%
SDS-polyacrylamide gel, and then transferred to a PVDF membrane. The
membrane was briefly washed with 1× Tris-buffered saline (TBS), and then
blocked in 5% milk dissolved in 1× TBST (1× TBS containing 0.1% Tween-20) for
1 h at room temperature. The membrane was then incubated in 1:1000 PDCD4
(Cell Signaling Technology, PDCD4 (D29C6) XP® Rabbit mAb) or GAPDH
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primary antibody (Cell Signaling Technology, GAPDH (D16H11) XP® Rabbit
mAb) in 1 × TBST containing 3% (w/v) BSA overnight at 4 °C. The membrane
was washed with 1 × TBST and incubated with 1:10000 anti-rabbit IgG
horseradish-peroxidase conjugate in 1 × TBS for 1 h at room temperature. After
washing with 1× TBST, protein expression was quantified using Clarity Western
ECL Substrate (Bio-Rad) per the manufacturer’s protocol. The image was
quantified with Image lab software. The quantification data provided were based
on three independent assays.
2.4.7 Cytotoxicity Assay
The cytotoxicity of 45A toward HEK293T and CHO cells were tested by MTT
assays (MTT = 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide).
HEK293T (50,000 cells/well) and CHO (25,000 cells/well) cells were seeded in
96-well plates and grown overnight to around 70% confluency. For the cell
viability under non-transfected condition, the cells were treated with or without
45A (5 µM) for 24 h. For the cell viability under transfection condition, the cells
were transfected with 100 ng of EGFP reporter plasmid (Actin-IRES-eGFP)116
following the method mentioned above and treated with or without 45A (5 µM) for
24 h. Subsequently, the medium was removed and 10 µL of MTT stock solution
(12 mM) was added to wells along with 100 µL of phenol free DMEM. The cells
were incubated at 37 oC for 4 h. The MTT containing medium was replaced with
50 µL of DMSO. The solution was mixed thoroughly with the pipette and
incubated 37 oC for 10 min. The absorbance at 540 nm was recorded with a plate
reader (SpectraMax i3X, Molecular Devices). The relative viability of the cells
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was calculated based on 6 parallel tests by comparing to the controls. The
results presented were based on three independent assays.
2.4.8 Translational Inhibition Assay
Translational inhibition was studied following a method modified from the
literature.113 HEK293T (2 × 105 cells/well) and CHO cells (1 × 105 cells/well) were
plated into 24-well plates and grown overnight to around 70% confluency. The
cells were then transfected with 400 ng of eGFP reporter plasmid (Actin-IRESeGFP)116 following the method mentioned above and treated with or without 45A
(5 µM). After 24 h, the cells were collected by trypsinizing and centrifugation. The
GFP expression was quantified with a microplate reader (SpectraMax i3X,
Molecular Devices). The relative cell viability obtained from the cytotoxicity assay
was used for normalizing the EGFP level. The assay was performed in triplicate.
The results presented were based on three independent assays.
2.4.9 Chemical Synthesis
Chemicals and instrumentation. Neomycin tri-sulfate was purchased from Sigma
Aldrich (Neomycin B > 85%). Kanamycin A was purchased from Amresco. All
other reagents and solvents were purchased from BroadPharm, Aldrich or Alfa
Aesar and used without further purification. Reactions involving air- or moisturesensitive reagents were performed under an argon atmosphere. Analytical thinlayer chromatography (TLC) was conducted on silica gel plates with fluorescent
indicator 254 nm, and compounds were visualized by irradiation (254 nm) or by
staining with ninhydrin stain or cerium ammonium molybdate stain. Column
chromatography was carried out on silica gel (pore size 60 Å, 200-425 mesh
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particle size, Sigma Aldrich). HPLC was performed using a Thermo Scientific
UltiMate 3000 semi-preparative system coupled with a Thermo Scientific Acclaim
120 C18 column (100 mm × 4.6 mm, 3 μm). All HPLC analyses were run at RT
and monitored at 260 nm. A gradient of CH3CN containing 0.1% TFA in water
containing 0.1% TFA was used at a flow rate of 1 mL/min. For analytical HPLC,
acetonitrile was increased from 5% to 90% in 25 min. For Prep-HPLC,
acetonitrile was increased from 5% to 19% in 10 min, 19% to 90% in 1 min and
then kept constant for 3 min. 1H and 13C NMR spectra were recorded on a Bruker
Avance III 300 spectrometer. Chemical shifts are reported in parts per million
(ppm, δ) referenced to the residual 1H resonance of the solvent.117 Splitting
patterns are designated as follows: s (singlet), d (doublet), t (triplet), m (multiplet),
br (broad). Coupling constants (J values) are listed in hertz (Hz). High resolution
mass spectra (HRMS) were obtained with a Waters Micromass mass
spectrometer with electrospray ionization probe.
Synthesis of KOF and KNF.
Compound 20118 To a solution of 5-hexynoic acid (2.0 g, 17.8 mmol) in
anhydrous THF (50 mL) was added N-hydoxysuccinimide (2.05 g, 17.8 mmol)
and DCC (3.68 g, 17.8 mmol). The reaction was stirred at room temperature for
overnight. The DCU solid was filtered out and the product was purified by column
chromatography (EA: Hexane = 1:2) to give 20 as a colorless oil (2.2 g, 60%). 1H
NMR (300MHz, CDCl3, δ) 2.84 (br, 4H), 2.78 (t, J = 7.5 Hz, 2H), 2.46 (m, 2H),
2.02 (t, J = 2.7 Hz, 1H), 1.97 (t, J = 7.2 Hz, 2H).
Compound 22104
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A solution of kanamycin (2.0 g, 3.43 mmol) in a mixture of DMF (40 mL), water (8
mL) and triethylamine (1 mL) was treated with di-tert-butyldicarbonate (3.1 g,
14.1 mmol). The reaction solution was heated to 60 ºC for 6 h, then cooled to
room temperature. The volatiles were removed in vacuo. The residue was
partitioned between water (300mL) and ethyl acetate (600 mL). The aqueous
layer was separated and extracted with ethyl acetate (2 × 150 mL). The
combined organic layer was washed with brine, dried over Na2SO4, and
concentrated in vacuo. The residue was purified by column chromatography
(MeOH: DCM = 1:10) to give 22 as a white solid (2.3 g, 76%). Rf = 0.2 (10%
methanol in dichloromethane). 1H NMR(300 MHz, MeOD, δ): 5.10 (br, 1H), 5.07
(d, J = 3.3 Hz, 1H), 4.07 (d, J = 8.7 Hz, 1H), 3.80-3.52 (m, 10H), 3.47-3.35 (m,
5H), 3.19(t, J = 9.3 Hz, 1H), 2.09 (d, J = 12.6 Hz, 1H), 1.45 (m, 37H).
Compound 23104
A solution of 22 (0.45 g, 0.51 mmol) in pyridine (10 mL) was treated with 2,4,6triisopropylbenzenesulfonyl chloride (2.5 g, 8.3 mmol). The reaction mixture was
stirred at room temperature for overnight and then neutralized by adding
hydrochloric acid (1.0 N). The mixture was partitioned between water (100 mL)
and ethyl acetate (200 mL). The aqueous layer was separated and extracted with
ethyl acetate (2 × 100 mL). The combined organic layer was washed with brine,
dried over Na2SO4, and concentrated in vacuo. The residue was purified by
column chromatography (50% to 100% EA in hexane) to give 23 a white solid
(0.46 g, 78%). Rf = 0.35 (Methanol: DCM = 1:10). 1H NMR (300 MHz, MeOD, δ)
7.28 (s, 2H), 5.04 (br, 2H), 4.38 (t, J = 10.2 Hz, 2H), 4.15 (m, 3H), 3.69 (br, 2H),
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3.61-3.35 (m, 11H), 3.16 (m, 1H), 2.95 (m, 1H), 2.01 (m, 1H), 1.45 (m, 36H), 1.25
(m, 19H).
Compound 24104
A solution of 23 (328 mg, 0.285 mmol) and cesium carbonate (1.10 g, 3.42 mmol)
in DMF (5 mL) was treated with cysteamine hydrochloride (0.65 g, 5.7 mmol).
The reaction mixture was stirred at 80 ºC for 4 h and then partitioned between
water (100 mL) and ethyl acetate (200 mL). The aqueous layer was separated
and extracted with ethyl acetate (2 × 150 mL). The combined organic layer was
washed with brine, dried over Na2SO4, and concentrated in vacuo. The residue
was purified by column chromatography (MeOH: DCM = 1:1) to give 24 as a
white solid (120 mg, 45%). Rf = 0.15 (15% methanol in dichloromethane). 1H
NMR (300 MHz, MeOD, δ) 5.09 (br, 1H), 5.03 (br, 1H), 4.15 (br, 1H), 3.67 (m,
2H), 3.59 (m, 3H), 3.53 (br, 2H), 3.52-3.32 (m, 5H), 3.17 (m, 1H), 3.02 (m, 2H),
2.97 (d, J = 7.8 Hz, 1H), 2.80 (m, 3H), 2.67 (m, 1H), 2.05 (m, 1H), 1.42 (m, 36H),
1.25 (m, 1H).
Compound 25
To a solution of 24 (100 mg, 0.106 mmol) in DCM (2 mL) was added TEA (50 µL)
and 20 (22.2 mg, 0.106 mmol). The reaction was stirred at 40 oC for 10 h. After
removal of the solvents, the residue was purified by column chromatography
(MeOH: DCM = 1:20) to give 25 as a white solid (50 mg, 45%). Rf = 0.55 (15%
MeOH in DCM). 1H NMR (300 MHz, MeOD, δ) 5.11 (br, 1H), 5.05 (br, 1H), 4.20
(br, 1H), 3.65 (m, 3H), 3.59 (m, 2H), 3.47 (m, 4H), 3.38 (m, 4H), 3.29 (m, 2H),
2.95 (m, 1H), 2.61 (m, 4H), 2.30 (m, 5H), 2.08 (br, 1H), 1.79 (m, 2H), 1.42 (m,
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36H), 1.26 (m, 1H).

13

C NMR (75 MHz, MeOD, δ): 175.44, 174.90, 159.41,

157.94, 157.72, 102.69, 99.91, 85.15, 84.25, 80.57, 80.38, 80.12, 77.02, 74.60,
74.05, 73.48, 72.33, 72.18, 71.76, 70.31, 57.13, 52.21, 50.89, 41.87, 40.21,
35.88, 34.57, 33.24, 29.95, 28.81, 28.40, 26.27, 25.92, 18.68. HRMS (ESI):
calculated for C46H79N5O19S [M + H]+ 1038.5168, found 1038.5146.
Compound 27119, 120
Compound 21 was first synthesized with a similar procedure as compound 20.
To a solution of kanamycin (free base, 0.243g, 0.5 mmol) in H2O (25 mL) was
added a solution of 21 (0.185 g, 0.5 mmol) in acetone (25 mL) dropwise at 15 ºC.
The reaction was stirred at room temperature for 1 h to produce compound 26
(not isolated). Boc2O (0.437 g, 2 mmol) was then added and the reaction was
stirred for 48 h. The precipitate was collected by filtration and purified by column
chromatography (MeOH: CHCl3: NH3·H2O = 1:4:0.1) to give 27 as a white solid
(0.240 g, 49%). Rf = 0.4 (MeOH: DCM: NH3·H2O = 1:5:0.1). 1H NMR (300 MHz,
DMSO and D2O, δ) 7.54 (br, 1H), 7.48 (br, 1H), 7.36 (m, 5H), 6.90 (br, 1), 6.54 (d,
J = 4.8 Hz, 1H), 6.50 (d, J = 5.4 Hz, 1H), 5.03 (s, 2H), 4.94 (s, 1H), 4.91 (s, 1H),
3.80 (br, 1H), 3.67 (m, 2H), 3.60 (m, 1H), 3.50 (m, 2H), 3.47-3.21 (m, 12H), 3.04
(m, 1H), 1.79 (br, 1H), 1.35 (m, 27H), 1.23 (m, 1H).

13

C NMR (75 MHz, DMSO

and D2O, δ): 170.11, 156.85, 156.75, 155.71, 155.29, 137.19, 128.68, 128.15,
127.99, 101.19, 98.07,84.04, 80.48, 78.35, 78.31, 77.71, 75.25, 73.15, 72.77,
72.27, 70.44, 70.34, 70.19, 67.57, 65.86, 60.49, 56.03, 50.31, 49.26, 43.59,
40.94, 29.29, 28.59, 28.48, 28.42. HRMS (ESI): calculated for C43H69N5O20 [M +
H]+ 976.4614, found 976.4660.

46

Compound 28
To a suspension of 27 (0.2g, 0.2 mmol) in MeOH (20 mL) was added Pd/C (10%,
0.05g). The mixture was stirred under H2 atmosphere (30 psi) for 4 h. The Pd/C
was filtered away and the solvents were evaporated in vacuum. The residue was
purified by column chromatography (MeOH: CHCl3: NH3·H2O = 1:1:0.1) to give
the product as a white solid (56 mg, 34%). Rf = 0.2 (MeOH: DCM: NH3·H2O =
1:1:0.1). 1H NMR (300 MHz, DMSO, δ) 7.77 (br, 1H), 6.92 (br, 1H), 6.61 (br, 1H),
6.51 (br, 1H), 4.91 (br, 2H), 4.23 (br, 1H), 3.80 (br, 1H), 3.63 (br, 1H), 3.50 (m,
6H), 3.35 (m, 5H), 3.24 (m, 3H), 3.03 (m, 2H), 1.79 (br, 1H), 1.38 (m, 27H), 1.23
(br, 1H).

13

C NMR (75 MHz, DMSO, δ): 172.45, 156.38, 155.37, 154.94, 101.16,

97.75, 84.16, 80.22, 77.87, 77.24, 74.99, 72.95, 72.78, 72.29, 70.34, 70.24,
70.10, 70.00, 67.35, 60.25, 55.90, 50.04, 49.02, 43.83, 34.79, 28.36, 28.25,
28.19. HRMS (ESI): calculated for C35H63N5O18 [M + H]+ 842.4246, found
842.4245.
Compound 29
Following the procedure for the synthesis of 25, Compound 28 (56 mg, 0.067
mmol), TEA (60 µL) and compound 20 (50 mg, 0.24 mmol), were used to give 29
(61 mg, 95%) as a white solid. Rf = 0.2 (DCM: MeOH: NH3·H2O = 5:1:0.1). 1H
NMR (300 MHz, DMSO, δ) 8.14 (br, 1H), 7.53 (br, 1H), 6.92 (br, 1H), 6.58 (br,
1H), 6.52 (br, 1H), 4.97 (br, 1H), 4.92 (br, 1H), 4.23 (br, 1H), 3.80 (m, 2H), 3.62
(m, 1H), 3.50 (m, 1H), 3.35-3.22 (m, 13H), 3.05 (br, 1H), 2.78 (s, 1H), 2.23 (br,
2H), 2.16 (br, 2H), 1.78 (br, 1H), 1.67 (br, 2H), 1.38 (m, 27H), 1.09 (br, 1H).

13

C

NMR (75 MHz, DMSO, δ): 172.09, 169.67, 156.39, 155.407, 154.95, 101.11,
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97.79, 84.12, 80.26, 77.92, 77.26, 75.07, 72.96, 72.69, 72.19, 71.50, 70.36,
70.12, 67.37, 64.96, 60.29, 55.93, 50.09, 48.98, 45.67, 42.04, 34.82, 33.97,
28.37, 28.25, 28.20, 24.28, 17.39, 15.21. HRMS (ESI): calculated for
C41H69N5O19 [M + Na]+ 958.4484, found 958.4487.
Compound 32
To a solution of 31 (0.15 g, 0.48 mmol) (synthesized following a reported
method121 and characterized by

1

H NMR) in DMF (5 mL) was added 6-

azidohexanoic (0.076g, 0.48 mmol), EDCI·HCl (0.10g, 0.528 mmol), HOBt (0.072
g, 0.528 mmol) and TEA (0.097 mg, 0.96 mmol). The reaction was stirred at
room temperature for overnight. The mixture was partitioned between water (20
mL) and EA (20 mL). The aqueous phase was separated and extracted with EA
(2 × 20 mL). The combined organic phase was dried with Na2SO4 and filtered.
After removing the solvents, the residue was purified by column chromatography
(MeOH: DCM = 1:25) to give 32 as a yellow solid (0.20 g, 90%). Rf = 0.4 (5%
MeOH in DCM). 1H NMR (300 MHz, CDCl3, δ) 8.57 (d, J = 7.5 Hz, 1H), 8.42 (d, J
= 8.4 Hz, 1H), 8.22 (d, J = 8.4 Hz, 1H), 7.65 (t, J = 7.5 Hz, 1H), 7.15 (s, 1H), 6.54
(d, J = 8.4 Hz, 1H), 6.17 (t, J = 6.0 Hz, 1H), 4.16 (t, J = 7.5 Hz, 2H), 3.77 (m, 2H),
3.48 (m, 2H), 3.13 (t, J = 6.6 Hz, 2H), 2.30 (t, J = 7.5 Hz, 2H), 1.73 (m, 4H), 1.55
(m, 2H), 1.48 (m, 2H), 1.42 (m, 2H), 0.95 (t, J = 7.5 Hz, 3H).

13

C NMR (75 MHz,

CDCl3, δ): 176.15, 164.55, 164.12, 150.12, 134.21, 130.87, 129.45, 127.20,
124.55, 122.28, 120.04, 109.05, 103.06, 50.98, 46.21, 39.83, 38.60, 36.08, 30.23,
28.43, 26.18, 25.17, 20.34, 13.81. HRMS (ESI): calculated for C24H30N6O3 [M +
H]+ 451.2458, found 451.2464.
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General procedure for the synthesis of KOF and KNF
Procedure A. To a solution of kanamycin alkyne (1 equiv) in DMSO (280 µL) and
H2O (40 µL) was added 32 (1 equiv), CuSO4 (0.1 equiv) and sodium ascorbate
(0.2 equiv). The reaction was stirred at room temperature for overnight. The
crude product was extracted with ethyl acetate and purified by chromatography
on a silica gel column using a DCM/MeOH mixture to give the Boc protected
conjugates.
Procedure B. The Boc protected conjugates was treated with TFA (1 mL) and
DCM (1 mL) for 24 h. The solvent and TFA were removed under reduced
pressure. The residue was purified by precipitation from a solution in MeOH by
Et2O (repeat 5 times), leading to the final product as solids (TFA salts).
KOF. General procedure A was employed for the reaction between 25 (10 mg,
0.01 mmol) and compound 32 (4.3 mg, 0.01 mmol), leading to the Boc protected
KOF as a yellow solid (8 mg, 52%). 1H NMR (300 MHz, DMSO, δ) 8.61 (d, J =
8.7 Hz, 1H), 8.44 (d, J = 7.2 Hz, 1H), 8.26 (d, J = 8.7 Hz, 1H), 8.10 (br, 1H), 7.90
(br, 1H), 7.85 (br, 1H), 7.81 (s, 1H), 7.70 (t, J = 7.5 Hz, 1H), 6.93 (br, 1H), 6.83 (d,
J = 8.7 Hz, 1H), 6.62 (br, 1H), 6.53 (d, J = 8.7 Hz, 1H), 6.37 (br, 1H), 5.48 (s, 1H),
5.26 (s, 1H), 4.22 (t, J = 7.5 Hz, 2H), 4.14 (m, 1H), 4.01 (t, J = 7.5 Hz, 2H), 3.603.10 (m, 13H), 2.57 (m, 4H), 2.08 (m, 4H), 1.77 (m, 5H), 1.55 (m, 4H), 1.37 (m,
36H), 1.25 (m, 5H), 0.93 (t, J = 7.5 Hz, 3H). HRMS (ESI): calculated for
C70H109N11O22S [M + Na]+ 1510.7367, found 1510.7410. General procedure B
was further applied to remove Boc and give KOF as a yellow solid (8.2 mg, 97%).
1

H NMR (300 MHz, D2O, δ) 7.98 (d, J = 7.5 Hz, 1H), 7.82 (d, J = 7.8 Hz, 1H),
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7.77 (d, J = 8.7 Hz, 1H), 7.31 (t, J = 7.8 Hz, 1H), 7.21 (s, 1H), 6.41 (d, J = 8.7 Hz,
1H), 5.51 (d, J = 3.6 Hz, 1H), 5.01 (d, J = 3.3 Hz, 1H), 3.92 (m, 2H), 3.85 (m, 2H),
3.69 (m, 4H), 3.61-3.32 (m, 9H), 3.27 (m, 2H), 3.17 (m, 2H), 2.95 (m, 1H), 2.63
(m, 2H), 2.47 (m, 2H), 2.11 (m, 4H), 1.84 (m, 1H), 1.71 (br, 2H), 1.26 (br, 7H),
0.85 (t, J = 7.5 Hz, 3H). HRMS (ESI): calculated for C50H77N11O14S [M + H]+
1088.5450, found 1088.5485.
KNF General procedure A was employed for the reaction between 29 (10 mg,
0.01 mmol) and compound 32 (4.3 mg, 0.01 mmol), leading to the Boc protected
KNF as a yellow solid (10 mg, 72%). 1H NMR (300 MHz, DMSO, δ) 8.58 (d, J =
5.4 Hz, 1H), 8.44 (d, J = 5.1 Hz, 1H), 8.26 (d, J = 8.4 Hz, 1H), 8.10 (br, 2H), 7.85
(s, 1H), 7.81 (s, 1H), 7.70 (m, 1H), 7.58 (s, 1H), 6.92 (m, 1H), 6.84 (d, J = 8.1 Hz,
1H), 6.59 (m, 2H), 5.39 (s, 1H), 5.22 (s, 1H), 5.0-2.3 (very poor resolution), 2.17
(m, 2H), 2.08 (m, 2H), 1.77 (m, 5H), 1.55 (m, 4H), 1.35 (m, 28H), 0.91 (t, J = 7.5
Hz, 3H). HRMS (ESI): calculated for C65H99N11O22 [M + Na]+ 1408.6864, found
1408.6891. General procedure B was applied to remove Boc and give KNF as a
yellow solid (9.9 mg, 98%). 1H NMR (300 MHz, D2O, δ) 7.88 (d, J = 6.0 Hz, 1H),
7.72 (d, J = 6.9 Hz, 1H), 7.68 (d, J = 7.5 Hz, 1H), 7.27 (s, 1H), 7.24 (d, J = 8.7 Hz,
1H), 6.33 (d, J = 6.0 Hz, 1H), 5.40 (d, J = 3.6 Hz, 1H), 5.05 (d, J = 3.6 Hz, 1H),
3.93 (m, 3H), 3.75 (m, 7H), 3.68 (m, 7H), 3.55 (m, 7H), 3.46 (m, 3H), 3.25 (t, J =
9.3 Hz, 1H), 2.48 (br, 3H), 2.20 (m, 2H), 2.18 (m, 2H), 1.92 (m, 1H), 1.76 (br, 2H),
1.41 (br, 5H), 1.32 (m, 4H), 0.91 (t, J = 7.2 Hz, 3H). HRMS (ESI): calculated for
C50H75N11O16 [M + H]+ 1086.5472, found 1086.5488.
Synthesis of NF
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Compound 35 was prepared according to a reference method.104
Compound 36
To a solution of 35 (200 mg, 0.157 mmol) in DCM (2 mL) was added 6azidohexanoic
ethylcarbodiimide

(30

mg,

0.188

hydrochloride

mmol),
(36

N-(3-Dimethylaminopropyl)-N-

mg,

0.188

mmol)

and

N,N-

diisopropylethylamine (49 mg, 0.377 mmol). The reaction was stirred at room
temperature for overnight. The mixture was partitioned between water (50 mL)
and ethyl acetate (50 mL). The aqueous phase was separated and extracted with
ethyl acetate (2 × 50 mL). The combined organic phase was washed with brine
(3 X 50 mL) and dried over Na2SO4. After removing the solvents, the residue was
purified by column chromatography (4.5% MeOH in DCM) to give 36 as a white
solid (96 mg, 43%). Rf = 0.5 (10% MeOH in DCM). 1H NMR (300 MHz, CD3OD, δ)
5.38 (s, 1H), 5.15 (s, 1H), 4.94 (s, 1H), 4.61 (s, 1H), 4.25 (br, 2H), 4.09 (m, 1H),
3.90 (m, 2H), 3.77 (s, 1H), 3.71 (m, 1H), 3.59 (m, 3H), 3.48 (m, 4H), 3.43 (m, 3H),
3.21 (m, 2H), 2.89 (d, J = 5.4 Hz, 2H), 2.76 (t, J = 6.6 Hz, 2H), 2.24 (t, J = 7.5 Hz,
2H), 1.94 (m, 1H), 1.66 (m, 4H), 1.45 (m, 61H).

13

C NMR (75 MHz, CD3OD, δ):

176.05, 159.08, 158.87, 158.49, 158.19, 158.15, 157.87, 111.09, 100.52, 99.14,
87.03, 82.71, 81.54, 80.74, 80.67, 80.58, 80.38, 80.22, 79.93, 75.63, 75.29,
74.47, 73.28, 72.86, 71.58, 68.86, 56.85, 53.60, 52.33, 51.45, 42.57, 41.75,
40.14, 36.94, 35.92, 35.56, 32.83, 29.65, 29.01, 28.88, 28.85, 28.77, 27.40,
26.52. HRMS (ESI): calculated for C61H109N10O25S [M + H]+ 1413.7286, found
1413.7264.
Compound 37 was prepared according to a reference method.122
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NF. A similar procedure as the synthesis of KOF was employed for the reaction
between 37 (10 mg, 7.3 µmol) and compound 32 (4.0 mg, 7.3 µmol), leading to
the Boc protected NF as a yellow solid (12 mg, 90%). 1H NMR (300 MHz, MeOD,
δ) 8.48 (d, J = 7.2 Hz, 1H), 8.42 (d, J = 8.4 Hz, 1H), 8.33 (d, J = 8.4 Hz, 1H), 7.70
(s, 1H), 7.65 (t, J = 8.1 Hz, 1H), 6.82 (d, J = 8.7 Hz, 1H), 5.37 (s, 1H), 5.15 (s,
1H), 4.93 (s, 1H), 4.24 (m, 4H), 4.12 (m, 3H), 3.90 (br, 2H), 3.76 (br, 2H), 3.59 (m,
8H), 3.48 (m, 4H), 3.39 (m, 4H), 3.31 (m, 1H), 2.90 (m, 2H), 2.74 (m, 4H), 2.22
(m, 4H), 1.95 (m, 3H), 1.85 (m, 2H), 1.63 (m, 6H), 1.45 (m, 54H), 1.28 (m, 5H),
0.96 (t, J = 7.5 Hz, 3H). HRMS (ESI): calculated for C85H135N13O28S [M + Na]+
1840.9158, found 1840.9204. The Boc was then removed by TFA to give NF as
a yellow solid (11 mg, 82%). 1H NMR (300 MHz, D2O, δ) 7.98 (d, J = 7.5 Hz, 1H),
7.82 (d, J = 8.1 Hz, 1H), 7.79 (d, J = 8.7 Hz, 1H), 7.30 (t, J = 8.1 Hz, 1H), 7.28 (s,
1H), 6.40 (d, J = 8.7 Hz, 1H), 6.04 (d, J = 3.9 Hz, 1H), 5.39 (s, 1H), 5.28 (s, 1H),
4.39 (s, 2H), 4.31 (m, 2H), 4.23 (m, 1H), 4.01 (m, 2H), 3.90 (m, 3H), 3.77 (m, 3H),
3.65 (m, 3H), 3.55 (m, 5H), 3.49-3.29 (m, 12H), 3.12 (m, 1H), 2.71 (m, 1H), 2.49
(m, 3H), 2.14 (m, 4H), 1.91 (m, 1H), 1.78 (m, 2H), 1.42 (m, 4H), 1.39 (m, 5H),
0.92 (t, J = 7.2 Hz, 3H). HRMS (ESI): calculated for C55H87N13O16S [M + 2H]2+
1219.6271, found 1219.6224.
Synthesis of bifunctional inhibitors
Compound 40
To a stirred solution of 2-(carboxymethyl)-5-hydroxybenzoic acid (39) (1.00 g) in
MeOH (50 mL) was added sulfuric acid (200 μL) dropwise. The mixture was
refluxed for 4 h. The solvents were removed by vacuum and the residue was
partitioned between water (50 mL) and ethyl acetate (50 mL). The organic phase
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was washed with water (2 X 50 mL) and dried over Na2SO4. The solid was
removed by filtration. The filtrate was vacuumed to remove the solvent. The
crude product was purified by chromatography (Hexane/Ethyl Acetate: 1/1) to
give 40 as a yellow oil (0.98 g, 86%). 1H NMR (300 MHz, DMSO): δ (ppm) 9.76
(s, 1H), 7.31 (d, J = 2.7 Hz, 1H), 7.16 (d, J = 8.4 Hz, 1H), 6.92 (dd, J = 8.4 Hz,
2.7 Hz, 1H), 3.84 (s, 2H), 3.75 (s, 3H), 3.57 (s, 3H).
Compound 41A
To a stirred solution of 40 (200 mg, 0.89 mmol) in DMF (5 mL) was added K2CO3
(370 mg) and propargyl bromide (400 mg, 80% in toluene, 2.68 mmol). The
reaction was stirred overnight at 70 oC. Water (50 mL) was added. The mixture
was extracted with ethyl acetate (2 X 50 mL). The combined organic phase was
washed with brine (3 X 50 mL) and dried over Na2SO4. The solid was filtered off.
The filtrate was vacuumed to remove the solvent. The residue was further
purified by chromatography (Hexane/Ethyl Acetate: 5/1) to give 41A as a yellow
oil (0.195 g, yield 83%). 1H NMR (300 MHz, MeOD): δ (ppm) 7.59 (d, J = 2.7 Hz,
1H), 7.24 (d, J = 8.4 Hz, 1H), 7.15 (dd, J = 8.4 Hz, 2.7 Hz, 1H), 4.77 (d, J = 2.4
Hz, 2H), 3.94 (s, 2H), 3.84 (s, 3H), 3.66 (s, 3H), 2.97 (t, J = 2.4 Hz, 1H). 13C NMR
(75 MHz, MeOD): δ (ppm) 174.2, 168.6, 158.1, 134.6, 131.8, 130.1, 120.0, 118.1,
79.4, 77.2, 56.8, 52.5, 52.3, 40.3. HRMS (ESI) m/z [M + Na]+ 285.0731,
calculated for C14H14O5Na 285.0739.
General method for compound 41B-D
To a stirred solution of 40 (1.1 eq) in THF was added appropriate alcohol (1 eq)
and triphenylphosphine (1.1 eq). The mixture was cooled to 5 oC with ice bath.
Diisopropyl azodicarboxylate (1.1 eq) was then added dropwise to maintain the
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temperature below 5 oC. The reaction was allowed to warm to room temperature
and stirred overnight. The solvents were removed by vacuum. The resulting
residue was dissolved in ethyl acetate (50 mL) and washed with saturated
sodium carbonate solution (3 X 50 mL). The organic phase was then dried,
concentrated and purified by chromatography (hexane/ethyl acetate). The crude
product (containing diisopropyl-1, 2-hydrazinedicarboxylate) was used for next
step reaction without further purification and characterization.
General method for compound 42A-C
To a solution of 41 (1 eq) in methanol (5 mL) was added water (5 mL) and
LiOH·H2O (4 eq). The reaction was stirred overnight at room temperature. The
solvents were removed by vacuum. The residue was dissolved in water (10 mL).
Concentrated HCl (2 mL) was added to adjust the pH to 1, resulting in white
precipitation. The solid was collected by filtration and dried to give the product as
a white solid.
Compound 42A
290 mg of 41A was used to produce 187 mg of 42A (white solid, yield 72%). 1H
NMR (300 MHz, MeOD): δ (ppm) 7.63 (d, J = 2.7 Hz, 1H), 7.23 (d, J = 8.4 Hz,
1H), 7.14 (dd, J = 8.4 Hz, 3.0 Hz, 1H), 4.77 (d, J = 2.4 Hz, 2H), 3.95 (s, 2H), 2.96
(t, J = 2.4 Hz, 1H).

13

C NMR (75 MHz, MeOD): δ (ppm) 175.8, 170.0, 157.9,

134.5, 132.4, 130.7, 119.8, 118.4, 79.5, 77.1, 56.8, 40.4. HRMS (ESI) m/z [M H]- 233.0451, calculated for C12H9O5 233.0450.
Compound 42B
340 mg of 41B was used to produce 111 mg of 42B (off white solid, 40% total
yield from 40). 1H NMR (300 MHz, MeOD): δ (ppm) 7.58 (d, J = 2.7 Hz, 1H), 7.22
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(d, J = 8.4 Hz, 1H), 7.10 (dd, J = 8.7 Hz, 2.7 Hz, 1H), 4.25 (d, J = 2.4 Hz, 2H),
4.18 (m, 2H), 3.94 (s, 2H), 3.89 (m, 2H), 2.88 (t, J = 2.4 Hz, 1H).

13

C NMR (75

MHz, MeOD): δ (ppm) 175.9, 170.2, 159.1, 134.6, 132.5, 130.2, 119.6, 117.9,
80.4, 76.1, 69.3, 68.6, 59.2, 40.4. HRMS (ESI) m/z [M - H]- 277.0705, calculated
for C14H13O6 277.0712.
Compound 42C
330 mg of 41C was used to produce 160 mg of 42C (white solid, 50% total yield
from 40). 1H NMR (300 MHz, MeOD): δ (ppm) 7.58 (d, J = 3.0 Hz, 1H), 7.21 (d, J
= 8.4 Hz, 1H), 7.10 (dd, J = 8.4 Hz, 2.7 Hz, 1H), 4.19 (m, 4H), 3.94 (s, 2H), 3.86
(m, 2H), 3.70 (m, 4H), 2.84 (t, J = 2.4 Hz, 1H).

13

C NMR (75 MHz, MeOD): δ

(ppm) 175.9, 170.2, 159.2, 134.6, 132.4, 130.1, 119.6, 118.0, 80.5, 75.9, 71.5,
70.7, 70.1, 68.8, 59.0, 40.4. HRMS (ESI) m/z [M - H]- 321.0969, calculated for
C16H17O7 321.0974.
Compound 42D
To a solution of 41D (330 mg) in methanol (5 mL) was added LiOH·H2O (233 mg)
and water (3 mL). The reaction was stirred overnight at room temperature. The
solvents were removed by vacuum. The residue was dissolved in water (10 mL).
Concentrated HCl (2 mL) was added to adjust the pH to 1. The mixture was then
extracted with ethyl acetate (2 X 10 mL). The combined organic phase was
washed with brine (2 X 10 mL), dried and concentrated to give 42D as colorless
oil (244 mg, 67% total yield from 40). 1H NMR (300 MHz, MeOD): δ (ppm) 7.58 (d,
J = 2.7 Hz, 1H), 7.22 (d, J = 8.4 Hz, 1H), 7.10 (dd, J = 8.4 Hz, 2.7 Hz, 1H), 4.17
(m, 4H), 3.94 (s, 2H), 3.86 (m, 2H), 3.71 (m, 2H), 3.65 (m, 6H), 2.83 (t, J = 2.4 Hz,
1H).

13

C NMR (75 MHz, MeOD): δ (ppm) 175.9, 170.1, 159.2, 134.6, 132.4,
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130.1, 119.6, 118.0, 80.6, 75.9, 71.7, 71.5, 71.4, 70.8, 70.1, 68.8, 59.0, 40.4.
HRMS (ESI) m/z [M - H]- 365.1232, calculated for C18H21O8 365.1236.
General method for Compound 43
A solution of 42 (1 eq) and O-(4-Methoxybenzyl)-hydroxylamine (1.2 eq) in
toluene (180 mL) was refluxed using a Dean-Stark apparatus overnight. The
solvent was removed by vacuum and the residue was purified by column
chromatography.
Compound 43A
42A (187 mg) was used to give 43A (174 mg) as a white solid. Elution solvent:
Hexane/Ethyl acetate 2/1; yield 62%. 1H NMR (300 MHz, CDCl3): δ (ppm) 7.76 (d,
J = 2.1 Hz, 1H), 7.52 (d, J = 8.7 Hz, 2H), 7.22 (m, 2H), 6.90 (d, J = 8.7 Hz, 2H),
5.08 (s, 2H), 4.77 (d, J = 2.1 Hz, 2H), 4.07 (s, 2H), 3.81 (s, 3H), 2.56 (t, J = 2.4
Hz, 1H).

13

C NMR (75 MHz, CDCl3): δ (ppm) 166.0, 161.5, 160.4, 157.2, 131.8,

128.9, 126.4, 126.2, 122.9, 114.0, 112.8, 78.1, 77.8, 76.4, 56.3, 55.4, 37.0.
HRMS (ESI) m/z [M + Na]+ 374.1008, calculated for C20H17NNaO5 374.1004.
Compound 43B
42B (111 mg) was used to give 43B (92 mg) as a white solid. Elution solvent:
Hexane/Ethyl acetate 2/1; yield 58%. 1H NMR (300 MHz, CDCl3): δ (ppm) 7.67 (d,
J = 2.4 Hz, 1H), 7.51 (d, J = 8.7 Hz, 2H), 7.20 (m, 2H), 6.90 (d, J = 8.4 Hz, 2H),
5.07 (s, 2H), 4.28 (d, J = 2.1 Hz, 2H), 4.23 (t, J = 4.5 Hz, 2H), 4.05 (s, 2H), 3.93 (t,
J = 4.5 Hz, 2H), 3.81 (s, 3H), 2.48 (t, J = 2.1 Hz, 1H). 13C NMR (75 MHz, CDCl3):
δ (ppm) 166.1, 161.6, 160.4, 158.5, 131.8, 128.8, 126.4, 126.2, 125.9, 123.0,
114.0, 112.0, 79.4, 78.2, 75.1, 68.1, 67.8, 58.8, 55.4, 37.1. HRMS (ESI) m/z [M +
Na]+ 418.1259, calculated for C22H21NNaO6 418.1267.
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Compound 43C
42C (160 mg) was used to give 43C (141 mg) as a white solid. Elution solvent:
Hexane/Ethyl acetate 1/1; yield 65%. 1H NMR (300 MHz, CDCl3): δ (ppm) 7.67 (d,
J = 2.4 Hz, 1H), 7.52 (d, J = 8.4 Hz, 2H), 7.21 (m, 2H), 6.90 (d, J = 8.7 Hz, 2H),
5.07 (s, 2H), 4.21 (m, 4H), 4.05 (s, 2H), 3.90 (t, J = 4.5 Hz, 2H), 3.81 (s, 3H),
3.75 (m, 4H), 2.44 (t, J = 2.4 Hz, 1H).

13

C NMR (75 MHz, CDCl3): δ (ppm) 166.1,

161.6, 160.4, 158.5, 131.8, 128.7, 126.3, 126.2, 125.7, 122.9, 113.9, 112.1, 79.7,
78.1, 74.8, 70.8, 69.7, 69.2, 68.0, 58.6, 55.4, 37.0. HRMS (ESI) m/z [M + Na]+
462.1531, calculated for C24H25NNaO7 462.1529.
Compound 43D
42D (244 mg) was used to give 43D (210 mg) as a white solid. Elution solvent:
Hexane/Ethyl acetate 3/4; yield 65%. 1H NMR (300 MHz, CDCl3): δ (ppm) 7.67 (d,
J = 2.4 Hz, 1H), 7.53 (dd, J = 6.6 Hz, 2.1 Hz, 2H), 7.19 (m, 2H), 6.90 (dd, J = 6.6
Hz, 2.1 Hz, 2H), 5.07 (s, 2H), 4.21 (m, 4H), 4.05 (s, 2H), 3.90 (t, J = 4.8 Hz, 2H),
3.81 (s, 3H), 3.76 (m, 2H), 3.68 (m, 6H), 2.43 (t, J = 2.1 Hz, 1H).

13

C NMR (75

MHz, CDCl3): δ (ppm) 166.1, 161.6, 160.4, 158.6, 131.8, 128.7, 126.3, 126.2,
125.7, 122.9, 113.9, 112.1, 79.8, 78.1, 74.7, 71.0, 70.8, 70.6, 69.7, 69.2, 68.0,
58.5, 55.4, 37.0. HRMS (ESI) m/z [M + Na]+ 506.1773, calculated for
C26H29NNaO8 506.1791.
Compound 44
To a stirred solution of 43A (27 mg, 0.077 mmol) in DCM (1.5 mL) was added
TFA (1.5 mL). The reaction turned to dark red after 4 h. The solvents were
removed by vacuum. The residue was washed with ether (3 X 1.5 mL) to give 44
as a white solid (15 mg, yield 81%). 1H NMR (300 MHz, DMSO): δ (ppm) 10.39
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(s, 1H), 7.57 (d, J = 2.4 Hz, 1H), 7.31 (m, 2H), 4.90 (d, J = 2.1 Hz, 2H), 4.18 (s,
2H), 3.60 (t, J = 2.1 Hz, 1H).

13

C NMR (75 MHz, DMSO): δ (ppm) 166.4, 161.5,

156.2, 129.1, 127.5, 126.0, 121.7, 111.9, 78.8, 78.7, 55.7, 36.2. HRMS (ESI) m/z
[M + H]+ 232.0616, calculated for C12H10NO4 232.0610.
General method for compound 45
To a solution of 36 (1 eq) in DMSO/H2O (400 µL/40 µL) was added 43 (1.2 eq),
sodium ascorbate (0.4 eq) and CuSO4 (0.2 eq). The reaction was stirred at room
temperature for 1 h. Water (5 mL) was added and the mixture was extracted with
ethyl acetate (3 X 10 mL). The combined organic phase was washed with brine
(3 X 10 mL), dried and concentrated. The residue was purified by preparative thin
layer chromatography (Prep-TLC), leading to a white solid. The solid was then
dissolved in a mixture of TFA and DCM (1 mL/1 mL). After being stirred overnight,
the reaction was vacuumed to remove the solvents. The residue was purified by
HPLC to give the final product.
Compound 45A
Solvent for Prep-TLC: 6% methanol in DCM. 36 (25 mg) was used to give 45A
(12 mg) as a white solid, yield 40%, keto form (100%), tR 6.2 min (analytical
HPLC method). 1H NMR (300 MHz, D2O): δ (ppm) 8.09 (s, 1H), 7.68 (d, J = 1.5
Hz, 1H), 7.36 (m, 2H), 6.04 (d, J = 3.6 Hz, 1H), 5.37 (d, J = 3.3 Hz, 1H), 5.33 (s,
2H), 5.27 (s, 1H), 4.42 (t, J = 6.0 Hz, 2H), 4.37 (d, J = 5.4 Hz, 1H), 4.33 (m, 3H),
4.21 (s, 1H), 4.10 (m, 1H), 4.00 (m, 1H), 3.92 (m, 2H), 3.82 (s, 1H), 3.75 (m, 2H),
3.58 (s, 2H), 3.48-3.55 (m, 4H), 3.38 (m, 3H), 3.27 (m, 3H), 3.09 (m, 1H), 2.75 (m,
1H), 2.62 (m, 2H), 2.49 (m, 1H), 2.11 (t, J = 7.2 Hz, 2H), 1.87 (m, 3H), 1.49 (m,
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2H), 1.10 (m, 2H). HRMS (ESI) m/z [M + H]+ 1044.4653, calculated for
C43H70N11O17S 1044.4672.
Compound 45B
Solvent for Prep-TLC: 6% methanol in DCM. 36 (50 mg) was used to give 45B
(23 mg) as a white solid, yield 37%, keto form (100%), tR 6.7 min (analytical
HPLC method). 1H NMR (300 MHz, D2O): δ (ppm) 7.97 (s, 1H), 7.55 (d, J = 2.7
Hz, 1H), 7.31 (d, J = 8.4 Hz, 1H), 7.25 (dd, J = 8.4 Hz, 2.7 Hz, 1H), 6.03 (d, J =
4.2 Hz, 1H), 5.37 (d, J = 3.0 Hz, 1H), 5.27 (s, 1H), 4.71 (m, 3H), 4.35 (m, 4H),
4.27 (m, 2H), 4.23 (m, 2H), 4.19 (m, 1H), 4.08 (m, 1H), 3.99 (m, 1H), 3.89 (m,
4H), 3.80 (s, 1H), 3.67 (m, 1H), 3.28-3.57 (m, 12H), 3.10 (m, 1H), 2.70 (m, 1H),
2.64 (m, 2H), 2.48 (m, 1H), 2.12 (t, J = 7.2 Hz, 2H), 1.82 (m, 3H), 1.49 (m, 2H),
1.13 (m, 2H). HRMS (ESI) m/z [M + H]+ 1088.4969, calculated for C45H74N11O18S
1088.4934.
Compound 45C
Solvent for Prep-TLC: 6.5% methanol in DCM. 36 (40 mg) was used to give 45C
(11 mg) as a white solid, yield 21%, keto form (50%), tR 7.0 min (analytical HPLC
method). 1H NMR (300 MHz, D2O): δ (ppm) 7.95 (s, 1H), 7.76 (d, J = 2.7 Hz, 1H),
7.51 (d, J = 8.4 Hz, 1H), 7.35 (dd, J = 8.4 Hz, 2.7 Hz, 1H), 6.04 (d, J = 3.9 Hz,
1H), 5.39 (s, 1H), 5.29 (s, 1H), 4.63 (m, 2H), 4.32 (m, 8H), 4.21 (m, 2H), 4.12 (m,
1H), 4.06 (m, 1H), 3.96 (m, 4H), 3.81 (s, 1H), 3.72 (m, 6H), 3.56 (m, 5H), 3.273.47 (m, 6H), 3.08 (m, 1H), 2.75 (m, 1H), 2.66 (m, 2H), 2.48 (m, 1H), 2.14 (m,
2H), 1.86 (m, 3H), 1.51 (m, 2H), 1.16 (m, 2H). HRMS (ESI) m/z [M + H]+
1132.5217, calculated for C47H78N11O19S 1132.5196.
Compound 45D
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Solvent for Prep-TLC: 7% methanol in DCM. 36 (40 mg) was used to give 45D (9
mg) as a white solid, yield 18%, keto form (60%), tR 7.2 min (analytical HPLC
method). 1H NMR (300 MHz, D2O): δ (ppm) 7.94 (s, 1H), 7.76 (d, J = 3.0 Hz, 1H),
7.50 (d, J = 8.4 Hz, 1H), 7.36 (dd, J = 8.4 Hz, 3.0 Hz, 1H), 6.04 (d, J = 3.9 Hz,
1H), 5.39 (s, 1H), 5.29 (s, 1H), 4.61 (m, 2H), 4.31-4.41 (m, 8H), 4.22 (m, 2H),
4.09 (m, 1H), 4.00 (m, 1H), 3.90 (m, 4H), 3.81 (s, 1H), 3.74 (m, 4H), 3.66 (m, 6H),
3.58 (m, 2H), 3.52 (m, 1H), 3.48 (s, 2H), 3.29-3.43 (m, 6H), 3.11 (m, 1H), 2.75 (m,
1H), 2.67 (m, 2H), 2.49 (m, 1H), 2.13 (m, 2H), 1.84 (m, 3H), 1.50 (m, 2H), 1.16
(m, 2H). HRMS (ESI) m/z [M + H]+ 1176.5500, calculated for C49H82N11O20S
1176.5458.
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Chapter 3 Design, synthesis and activity of light deactivatable miRNA
inhibitor
3.1 Introduction
Each miRNA typically targets multiple mRNAs and its function usually depends
on the local cellular context.123-126 In cells, miRNAs are found to be transported to
or matured/produced at different sub-cellular locations to achieve spatiotemporal
specific regulation of target mRNAs.127 To dissect the dynamic and context
dependent function of miRNAs, spatiotemporal controllable miRNA regulators are
required. Current methods for this purpose rely on the application of optical
controllable probes.128 By modifying synthetic antisense oligonucleotides (ASOs)
with photo-removable caging groups, the hybridizations of ASOs with target
RNAs are suppressed. Upon light irradiation, the caging groups can be removed
and the active ASOs can be regenerated to block the function of targeted
RNAs.129-131 By incorporating photo-cleavable moieties between nucleotides of
ASOs, these modified ASOs can be fragmented and inactivated by light.132
However, using ASOs faces several limitations including poor cellular uptake
efficiency and bio-distribution.70 As a result, small-molecule inhibitors targeting
different steps of the miRNA biogenesis have been developed.61,

102, 133-136

Unfortunately, no inhibitor allowing photo control of its activity to achieve
spatiotemporal regulation of miRNAs has been reported so far.
In Chapter 2, we developed a strategy to regulate miRNA biogenesis by using
bifunctional small molecules inhibiting the Dicer processing of pre-miRNA.137
These molecules consist of a pre-miRNA binding unit and a low affinity Dicer
inhibiting unit. Neither of these 2 individual units inhibits miRNA maturation by
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itself. However, when the two units are conjugated through a linker, the premiRNA binder can deliver the Dicer inhibiting unit to the catalytic cleavage site of
Dicer in the targeted pre-miRNA/Dicer complex, which increases the effective
local concentration of the weak Dicer inhibitor, thus achieving the blockage of the
Dicer-mediated miRNA maturation.137 Because of the bi-modular design of this
strategy, we envisioned that using a photo cleavable linker to conjugate the two
functional units should give a light-responsive bifunctional molecule that allow
photo-induced fragmentation of the active bifunctional inhibitor into 2 separate
inactive units to achieve deactivation, thus offering quick and potentially spatial
controlled reversion of the inhibitory effects, which has significant importance for
studying miRNA function.

Figure 3.1 Design of light controllable miR-21 inhibitor.. 16
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3.2 Results and discussion
3.2.1 Design and synthesis of light controllable miRNA inhibitor
We previously showed that neither compound 38, a weak Dicer inhibitor, nor
neomycin, a pre-miR-21 binder (Figure 3.1), can inhibit the Dicer-mediated
maturation of miR-21 even at high µM or mM concentrations.137 However, the
conjugates of these 2 units gave bifunctional molecules that almost completely
inhibit miR-21 maturation at 5 µM.137 To test the feasibility of the light
deactivation approach with bifunctional molecules as proposed above, we
conjugated 38 and neomycin with a photo cleavable linker with a comparable
length to the linker used in previously reported active bifunctional miR-21
inhibitors.

Ortho-nitrobenzyl

(NB)

derivatives

are

commonly

used

as

photocleavable linkers or caging groups to offer photo-induced controls of NBconjugated molecules.138 The light irradiation condition for the cleavage of NB
groups has been shown to be compatible with biological applications.130, 139-141 As
a result, we designed light deactivatable bifunctional miR-21 inhibitor 46 (Figure
3.1) by incorporating the photocleavable 4,5-dimethoxy-2-nitrobenzyl (DMNB)
group into the linker.
The synthetic route of 46 was shown in Figure 3.2. An azide equipped NB
compound 50 was synthesized from 4, 5-dimethoxy-6-nitrobenzaldehyde by
multistep modifications, which was then conjugated to 53 by 1,1’-carbonyl
diimidazole to generate 54. The ester groups of 54 were hydrolyzed steadily by
LiOH to give homophthalic acid derivative 55, which was then cyclized by O(tetrahydro-2H-pyran-2-yl)hydroxylamine following a reported method142 to yield
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56. The alkynyl modified neomycin122 was conjugated to 56 through click
chemistry to afford the target compound 46.
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Figure 3.2 Synthetic scheme of light deactivable miR-21 inhibitor 46.. 17
3.2.2 Photolysis study by HPLC
With the bifunctional inhibitor 46 in hand, we first checked whether the DMNBcontaining linker in 46 can be cleaved by photo irradiation. Solutions of 46 (125
µM) in PBS (pH 7.4) were irradiated with 365 nm UV light under a fluorescence
microscopy. Time course HPLC analysis of the photolysis reactions clearly
showed that 46 rapidly disappeared upon irradiation (Figure 3.3), while two major
peaks, likely corresponding to the fragmented products (Figure 3.1), were
generated. These results indicated that bifunctional inhibitor 46 could be
fragmented by photo irradiation. The fast reaction speed, complete within 30 s, is
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desirable for biological applications that require fast stimuli response and minimal
irradiation dose to avoid the phototoxicity introduced by UV irradiation.

Figure 3.3 (a) Time course HPLC analysis of the photolysis reactions of 46. (b)
Quantification of the relative amount of 46 left over in reactions as in panel (a).. 18
3.2.3 In vitro Dicer inhibition activity
We then studied the Dicer inhibition activity of 46 before and after photo
irradiation.

32

P-labeled pre-miR-21, prepared by in vitro transcription, was

incubated with recombinant human Dicer in the absence or presence of 46. The
processing of pre-miR-21 into mature miR-21 by Dicer was then monitored by
denaturing polyacrylamide gel electrophoresis along with phosphor imaging.137
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As shown in Figure 3.4, Dicer efficiently processed pre-miR-21 into mature miR21 (Lane 2). To test if the inhibitory activity of the bifunctional inhibitor still

Figure 3.4 (a) Representative image from electrophoresis analysis of Dicermediated pre-miR-21 cleavage in the presence of varing concentrations of 46
with or without UV (365 nm, 30 s) irradiation. (b) Densitometric quantitative
analysis of miR-21 for images in panel a arising from three independent assays.
Error bars represent the standard error of mean (N = 3).. 19
remains after introducing the DMNB group into the linker, different concentrations
of 3 (2 - 8 µM) were co-incubated with

32

P-labeled pre-miR-21 and Dicer during

the processing reaction and a dose dependant inhibition of miR-21 production
was observed (Lane 3-5). These results confirm that the photo-cleavable linker
does not affect the activity of the bifunctional inhibitor 46. To test the light-

66

induced deactivation, 46 (8 µM) was pre-irradiated with UV (365 nm, 30 s) before
adding to the Dicer-mediated pre-miR-21 processing reaction (Lane 6).
Compared to the condition treated with non-irradiated 46 at the same
concentration, the production of mature miR-21 was clearly increased under the
irradiated condition (Lane 5 vs 6), indicating that light irradiated 46 indeed loses
its inhibitory activity. Overall, these results demonstrate that 46 could serve as a
miR-21 inhibitor, and that photo irradiation could deactivate its ability to inhibit
pre-miR-21 processing by Dicer.
3.3 Summary
Light controllable miRNA regulators could offer an invaluable tool for studying
miRNA functions through manipulating the activity or levels of miRNAs with
spatiotemporal preciseness. By conjugating a Dicer inhibitor 38 and a pre-miR-21
binder (neomycin) with a photo-cleavable linker, we prepared a light
deactivatable bifunctional miR-21 inhibitor 46 that inhibits pre-miR-21 processing
by Dicer. The linker cleavage of 46 by photo irradiation separated the two
functional units in 46 and deactivated the inhibitor. To our knowledge, this is the
first reported light controllable miRNA regulator based on a small molecule
instead of ASOs. By making bifunctional conjugates with RNA binders targeting
other pre-miRNAs, we expect the strategy described in this work could be
applied for regulating other miRNAs in a spatiotemporal manner, which would
provide important chemical biology tools for miRNA studies.
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3.4 Experimental section
3.4.1 Chemistry
Chemicals and instrumentation. As described in 2.4.9. HPLC was performed
using a Thermo Scientific UltiMate 3000 semi-preparative system coupled with a
Thermo Scientific Acclaim 120 C18 column (100 mm × 4.6 mm, 3 μm). All HPLC
analyses were run at RT and monitored at 260 nm. A gradient of CH3CN
containing 0.1% TFA in water containing 0.1% TFA was used at a flow rate of 1
mL/min. For analytical HPLC, acetonitrile was increased from 5% to 90% in 25
min (Method A). For Prep-HPLC, acetonitrile was increased from 5% to 60% in
15 min, 60% to 95% in 0.5 min and then kept constant for 3 min (Method B).
Ethyl 3-(4,5-dimethoxy-2-nitrophenyl)-3-hydroxypropanoate (47).
To

an

argon-purged

flask

was

added

THF

(25

mL)

and

sodium

hexamethyldisilazide solution (2 M, 2.6 mL). A solution of ethyl acetate (0.463 g,
5.25 mmol) in THF (5 mL) was then added dropwise at -78 °C. The mixture was
stirred for 0.5 h, after which a solution of 4, 5-dimethoxy-6-nitrobenzaldehyde
(1.025 g, 4.84 mmol) in THF (20 mL) was added dropwise. The reaction was
allowed to warm to room temperature and then quenched by saturated NaCl
solution (50 mL). The mixture was extracted by ethyl acetate (2 × 50 mL). The
combined organic phase was dried over MgSO4 and concentrated by vacuum.
The residue was purified by chromatography (ethyl acetate/hexane = 1:2) to give
the product as a white solid (0.911 g), yield 63%. 1H NMR (500 MHz, CDCl3, δ)
7.63 (s, 1H), 7.38 (s, 1H), 5.80 (dt, J = 9.3 Hz, 2.7 Hz, 1H), 4.22 (q, J = 7.2 Hz,
2H), 4.00 (s, 3H), 3.95 (s, 3H), 3.85 (d, J = 3.0 Hz, 1H), 2.98 (dd, J = 16.5 Hz, 2.7
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Hz, 1H), 2.58 (dd, J = 16.5 Hz, 9.3 Hz, 1H), 1.30 (t, J = 7.2 Hz, 3H). 13C NMR (75
MHz, CDCl3, δ): 172.79, 154.00, 148.09, 139.42, 133.83, 109.13, 107.87, 66.31,
61.26, 56.60, 56.50, 42.42, 14.29. HRMS (ESI): calculated for C13H17NO7 [M +
Na]+ 322.0903, found 322.0904.
1-(4,5-dimethoxy-2-nitrophenyl)propane-1,3-diol (48).
To a solution of Compound 47 (900 mg, 3 mmol) in methanol (50 mL) was added
NaBH4 (345 mg, 9 mmol) in small portions. The reaction was stirred at room
temperature for overnight. The solvents were removed by vacuum. The residue
was dissolved in a solution of HCl (0.5 M, 50 mL) and extracted with ethyl
acetate (3 × 30 mL). The combined organic phase was dried over MgSO4 and
concentrated by vacuum. The crude product was purified by chromatography
(ethyl acetate/hexane = 2:1) to give the product as a yellow solid (764 mg), yield
98%. 1H NMR (300 MHz, CDCl3, δ) 7.61 (s, 1H), 7.39 (s, 1H), 5.66 (dt, J = 9.0 Hz,
2.4 Hz, 1H), 4.06 (m, 5H), 3.95 (s, 3H), 3.59 (d, J = 2.7 Hz, 1H), 2.23 (t, J = 4.2
Hz, 1H), 2.13 (m, 1H), 1.98 (m, 1H).

13

C NMR (75 MHz, CDCl3, δ): 153.90,

147.82, 139.34, 135.92, 109.14, 107.80, 70.25, 62.37, 56.57, 56.47, 39.72.
HRMS (ESI): calculated for C11H15NO6 [M + Na]+ 280.0797, found 280.0783.
3-(4,5-dimethoxy-2-nitrophenyl)-3-hydroxypropyl 4-methylbenzenesulfonate (49).
To a solution of Compound 48 (111 mg, 0.432 mmol) in pyridine (3 mL) was
added p-toluenesulfonyl chloride (164 mg, 0.863 mmol). The reaction was stirred
at room temperature for 5 h. The solvents were removed by vacuum. The
resulting residue was dissolved in ethyl acetate (30 mL) and washed with HCl
(0.5 M, 20 mL) solution. The organic phase was dried over MgSO4 and
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concentrated by vacuum. The residue was purified by chromatography (ethyl
acetate/hexane = 1:1) to give the product as yellow oil (95 mg), yield 54%. 1H
NMR (500 MHz, CDCl3, δ) 7.81 (d, J = 8.0 Hz, 2H), 7.57 (s, 1H), 7.34 (d, J = 8.0
Hz, 2H), 7.26 (s, 1H), 5.46 (dd, J = 9.0 Hz, 2.5 Hz, 1H), 4.39 (m, 1H), 4.28 (m,
1H), 3.98 (s, 3H), 3.93 (s, 3H), 2.45 (s, 3H), 2.21 (m, 1H), 1.97 (m, 1H). 13C NMR
(125 MHz, CDCl3, δ): 153.94, 148.09, 145.06, 139.53, 134.89, 133.00, 130.03,
128.06, 109.10, 107.93, 67.80, 66.65, 56.62, 56.50, 37.17, 21.80. HRMS (ESI):
calculated for C18H21NO8S [M+Na]+ 434.0886, found 434.0886.
3-azido-1-(4,5-dimethoxy-2-nitrophenyl)propan-1-ol (50).
To a solution of Compound 49 (93 mg, 0.23 mmol) in DMF (3 mL) was added
sodium azide (147 mg, 2.3 mmol). The reaction was stirred at 70 °C for 4 h. The
mixture was partitioned between water (10 mL) and ethyl acetate (10 mL). The
aqueous phase was extracted with ethyl acetate (1×10 mL). The combined
organic phase was then washed with brine (3×10 mL) and dried over MgSO4.
The solvents were removed by vacuum and the residue was purified by
chromatography (ethyl acetate/hexane = 1:3) to give the product as a yellow solid
(46 mg), yield 72%. 1H NMR (300 MHz, CDCl3, δ) 7.55 (s, 1H), 7.29 (s, 1H), 5.47
(d, J = 8.7 Hz, 1H), 3.99 (s, 3H), 3.93 (s, 3H), 3.59 (t, J = 6.3 Hz, 2H), 3.07 (s,
1H), 2.12 (m, 1H), 1.91 (m, 1H).

13

C NMR (75 MHz, CDCl3, δ): 153.78, 147.81,

139.22, 135.54, 108.83, 107.71, 67.56, 56.47, 56.35, 48.93, 37.03. HRMS (ESI):
calculated for C11H14N4O5 [M-OH]+ 265.0931, found 265.0906.
Methyl 5-(2-aminoethoxy)-2-(2-methoxy-2-oxoethyl)benzoate (53). Compound 51
was prepared as reported.109, 137 To a solution of 51 (0.224 g, 1 mmol) in THF (5
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mL) was added N-Boc-ethanolamine (0.177 g, 1.1 mmol) and triphenylphosphine
(0.289 g, 1.1 mmol). The mixture was cooled down to 5 °C. Diisopropyl
azodicarboxylate (0.222 g, 1.1 mmol) was then added dropwise to maintain the
temperature below 5 °C and the reaction was stirred at room temperature for
overnight. After removing the solvents by vacuum, the residue was purified by
chromatography (Hexane:Ethyl Acetate = 3:1) to give 52 as a yellow oil. The
crude product was subject to Boc removal without further purification. It was
dissolved in a mixture of dichloromethane (6 mL) and trifluoroacetic acid (3 mL).
The mixture was stirred at room temperature for overnight. The solvents were
removed by vacuum and the residue was partitioned between saturated Na2CO3
solution (15 mL) and ethyl acetate (15 mL). The aqueous phase was then
extracted with ethyl acetate (3×15 mL). The combined organic phase was then
washed with brine (1×15 mL) and dried with Na2SO4. After removing the solvents
by

vacuum,

the

residue

was

purified

by

chromatography

(MeOH:Dichloromethane = 1:10) to give the product as an off-white solid (0.183
g), yield 69% for two steps. 1H NMR (300 MHz, CDCl3, δ) 7.56 (d, J = 2.7 Hz, 1H),
7.16 (d, J = 8.4 Hz, 1H), 7.29 (dd, J = 8.4 Hz, 2.7 Hz, 1H), 4.03 (t, J = 5.1 Hz, 2H),
3.93 (s, 2H), 3.87 (s, 3H), 3.70 (s, 3H), 3.10 (t, J = 5.1 Hz, 2H).

13

C NMR (75

MHz, CDCl3, δ): 172.49, 167.45, 158.05, 133.51, 130.63, 128.39, 119.01, 116.77,
70.39, 52.22, 52.06, 41.56, 39.85. HRMS (ESI): calculated for C13H17NO5 [M+H]+
268.1185, found 268.1194.
Compound 54
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To a solution of compound 50 (46 mg, 0.16 mmol) in dichloromethane (3 mL)
was added 1,1’-carbonyldiimidazole (79 mg, 0.49 mmol). The reaction was
stirred at room temperature for 24 h. The reaction was diluted with
dichloromethane (20 mL) and washed with H2O (3×20 mL). The solution was
then dried with MgSO4 and the solvents were removed by vacuum. The residue
was dissolved in THF (3 mL). To the mixture was added compound 53 (62 mg,
0.23 mmol) and the reaction was refluxed for 8 h, after which it was diluted with
dichloromethane (20 mL) and washed sequentially with HCl solution (0.1 M, 2×10
mL) and H2O (1×15 mL). The organic phase was dried with MgSO4 and purified
by chromatography (ethyl acetate/hexane = 1:1) to give the product as an offwhite solid (80 mg), yield 85%. 1H NMR (300 MHz, CDCl3, δ) 7.61 (s, 1H), 7.52
(d, J = 2.7 Hz, 1H), 7.17 (d, J = 8.7 Hz, 1H), 7.01 (d, J = 3.0 Hz, 1H), 6.97 (s, 1H),
6.38 (dd, J = 9.0 Hz, 3.0 Hz, 1H), 5.39 (t, J = 5.7 Hz, 1H), 4.03 (m, 2H), 3.93 (m,
5H), 3.88 (s, 3H), 3.87 (s, 3H), 3.69 (s, 3H), 3.57 (m, 2H), 3.48 (m, 2H), 2.26 (m,
1H), 2.10 (m, 1H). 13C NMR (75 MHz, CDCl3, δ): 172.31, 167.13, 157.47, 155.18,
153.81, 148.24, 139.85, 133.59, 132.06, 130.70, 128.77, 118.53, 116.70, 107.96,
70.41, 67.15, 56.46, 52.22, 52.01, 48.21, 40.61, 39.73, 35.37. HRMS (ESI):
calculated for C25H19N5O11 [M+Na]+ 598.1761, found 598.1768.
Compound 55
To a solution of 54 (80 mg, 0.14 mmol) in THF (1 mL) was added LiOH (13 mg,
0.31 mmol, in 1 mL of water) dropwise at 0 °C. The reaction was allowed to warm
to room temperature and stirred for overnight. Then a solution of HCl (0.5 M, 10
mL) was added and the mixture was extracted with ethyl acetate (3×10 mL). The
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combined organic phase was washed with brine (1×10 mL) and dried over
MgSO4. The solid was filtered off, after which the solvents were removed under
vacuum to give the product as a white solid (64 mg), yield 84%. 1H NMR (500
MHz, CD3OD, δ) 7.64 (s, 1H), 7.52 (d, J = 2.5 Hz, 1H), 7.17 (d, J = 8.5 Hz, 1H),
7.10 (s, 1H), 6.99 (dd, J = 8.5 Hz, 2.5 Hz, 1H), 6.32 (dd, J = 9.5 Hz, 2.5 Hz, 1H),
4.00 (m, 2H), 3.93 (s, 2H), 3.88 (s, 3H), 3.79 (s, 3H), 3.49 (m, 4H), 2.23 (m, 1H),
2.06 (m, 1H).

13

C NMR (125 MHz, CD3OD, δ): 175.85, 170.07, 159.08, 157.84,

155.40, 149.64, 141.01, 134.59, 133.53, 132.45, 130.20, 119.21, 118.00, 109.53,
108.97, 70.92, 68.12, 56.79, 41.43, 40.44, 36.18. HRMS (ESI): calculated for
C23H25N5O11 [M+Na]+ 570.1448, found 570.1457.
Compound 56
To a solution of 55 (60 mg, 0.11 mmol) in chlorobenzene was added O(tetrahydro-2H-pyran-2-yl)hydroxylamine (19 mg, 0.16 mmol). The reaction was
refluxed for overnight and the solvents were removed by vacuum. The residue
was dissolved in methanol (5 mL). To the solution was then added ptoluenesulfonic acid (21 mg, 0.11 mmol). The mixture was stirred at room
temperature for 8 h. After removing the solvents, the residue was triturated with
H2O (2×5 mL) and ether (2×5 mL) sequentially and then purified by prep-HPLC
(Method B) to give the product as an off-white solid (30 mg), yield 50%. 1H NMR
(300 MHz, DMSO, δ) 10.40 (br, 1H), 7.74 (t, J = 5.1 Hz, 1H), 7.60 (s, 1H), 7.43 (d,
J = 2.4 Hz, 1H), 7.28 (d, J = 8.4 Hz, 1H), 7.17 (dd, J = 8.7 Hz, 2.7 Hz, 1H), 7.08
(s, 1H), 6.15 (dd, J = 8.4 Hz, 3.9 Hz, 1H), 4.18 (s, 2H), 4.02 (t, J = 5.1 Hz, 2H),
3.86 (s, 3H), 3.82 (s, 3H), 3.51 (m, 2H), 3.34 (m, 2H), 2.28 (m, 1H), 2.10 (m, 1H).
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13

C NMR (75 MHz, DMSO, δ): 166.45, 161.55, 157.42, 155.35, 153.39, 147.74,

139.41, 131.67, 129.08, 126.83, 125.98, 121.11, 111.43, 108.55, 107.63, 68.28,
66.78, 56.09, 47.34, 38.42, 36.19, 34.49. HRMS (ESI): calculated for
C23H24N6O10 [M+Na]+ 567.1452, found 567.1460.
Compound 46
The TFA salt of Compound 57 was prepared as reported.122 To a solution of 56
(4 mg, 0.007 mmol) and 57 (9 mg, 0.006 mmol) in DMSO (200 µL) was added
CuSO4 (0.35 mg, 0.0014 mmol, in 10 µL of water) and sodium ascorbate (0.55
mg, 0.0028 mmol, in 10 µL of water). The mixture was protected under argon and
incubated at room temperature for 8 h, after which it was purified by prep-HPLC
(Method B) to give the product as an off-white solid (3.1 mg), yield 25%, tR 8.2
min (analytical HPLC Method A). The compound was characterized by 1H NMR
(500 MHz, D2O) which shows the presence of both neomycin and the inhibitor
moieties. HRMS (ESI): calculated for C54H81N13O23S [M+H]+ 1312.5367, found
1312.5396; [M+2H]2+ 656.7723, found 656.7751.
3.4.2 Photolysis study
The photolysis reaction of 46 was performed with an Axio Observer (Zeiss)
microscope equipped with an HBO103 W/2 mercury arc lamp. 50 µL of 46 (125
µM in PBS buffer) was added in 96-well plate. The plate was irradiated using a
DAPI filter, set with peak excitation at 365 nm. No objective lens was used, which
created an area of illumination that completely covered one well of a 96-well
plate. Light was transmitted through the polystyrene plate bottom. The reaction
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was followed by HPLC (Method A). The relative amount of 46 was calculated by
normalizing the peak integration to that before irradiation.
3.4.3 Dicer enzyme expression
Dicer enzyme was expressed with a plasmid coding Flag tagged Dicer
(Addgene plasmid # 41584)143 in HEK293T cells and purified by anti-Flag M2
affinity gel (Sigma-Aldrich). HEK293T cells were cultured in DMEM medium
(Gibco) without antibiotics, supplemented with 10% FBS and 2 mM GlutaMAX
(Life Technologies) at 37 °C in a humidified atmosphere containing 5% CO2. The
cells were plated in 15-cm dish and grown overnight to 60% confluency.
Lipo3000 transfection reagent (Invitrogen) was used to transfect the cells with the
plasmid DNA (9 μg) per the manufacture’s protocol. After 60 h incubation, the
medium was removed. The cells were then washed with PBS and lysed in 1 mL
of lysis buffer (Tris 50 mM, NaCl 150 mM, Triton X-100 1%, SDS 0.1%, pH 7.5)
containing Cocktail protease inhibitor (ThermoFisher). The lysate was centrifuged
at 4 °C , 15000 RPM, for 10 min. The supernatant was then incubated with 60 μL
of ANTI-FLAG M2 Affinity Gel at 4 °C with gentle agitation for 16 h. The gel was
then washed with buffer (Tris 50 mM, NaCl 150 mM, NP-40 0.005%, pH 7.5) and
suspended in H2O (25 μL) and glycerol (25 μL) for storage at -20 °C. The
enzyme on gel was used directly for the following assay without cleavage.
3.4.4 In vitro Dicer inhibition assay
32

P-labeled pre-miR-21 was prepared as described before.137 Right before use,

the RNA was allowed to refold as follows: RNA was heated to 94 oC for 2 min
and then cooled to 4 oC at a rate of 1 oC/s. A 10 µL of the reaction mixture was
75

made by mixing

32

P-labeled pre-miR-21 (1 µL, ̴ 20 ng) with Dicer enzyme (3 µL)

and various concentrations of 46 with or without photolysis (365 nm, 30 s) in
buffer (HEPES 24 mM, NaCl 200 mM, EDTA 0.04 mM, MgCl2 2.5 mM, ATP 1
mM, pH 7.5). The reactions were incubated at 37 °C for 5 h and stopped by
boiling with equal volume of Gel Loading Buffer II (ThermoFisher Scientific) for 5
min. The non-cleaved pre-miR-21 and the processed miR-21 were resolved by
18% denaturing polyacrylamide gel electrophoresis. The gel was imaged by
phosphor imaging and analyzed with Quantity one software (Bio-rad).
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Chapter 4 MiRNA inhibition by macrocyclic peptidomimetics
This chapter is based on joint work with Dr. Jianfeng Cai’s research group at the
University of South Florida.
4.1 Introduction
Most of the currently developed miRNA inhibitors are comprised of
polycationic scaffolds similar to those present in aminoglycosides. Unfortunately,
these substances suffer from non-specific targeting and poor cell permeability.73,
82, 83

Thus, despite the fact that significant progress has been made in this area,

the development of small molecules that target miRNA precursors with high
specificity and cell permeability remains a challenging task.
Peptidomimetics are peptides that contain unnatural polyamide backbones
comprised of diverse side chains. Compared to natural peptides, these
substances possess a high degree of chemical diversity, protease resistance and
bioavailability.144 Consequently, peptidomimetics represent a family that serves
as a rich source for discovering novel binders and inhibitors for biological targets.
Moreover, head to tail backbone cyclization of these substances can be utilized
to improve exopeptidase resistance and enhance structural rigidity. Thus, the
development and applications of cyclic peptidomimetics have become areas of
increasing interest.145-148
Peptides92, 134 and linear peptoids,74 several of which contain polycationic side
chains, have recently been found to bind and inhibit processing of pre-miRNAs.
Inspired by these findings, we envisioned that cyclic peptidomimetics would
serve as a new type of scaffold for targeting pre-miRNA. Moreover, we felt that a
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compound library comprised of these substances would have a significantly high
diversity and that screening of this library has the potential of uncovering nonpolycationic inhibitors of miRNAs that could have improved specificity.
MiR-155, one of the key oncogenic miRNAs overexpressed in several human
cancers,149 promotes tumor formation through suppression of apoptosis and
facilitation of cancer cell proliferation.150 Because its downregulation has been
shown to induce apoptosis of cancer cells and to block tumor growth in mice,151,
152

miR-155 is a promising anti-cancer therapeutic target. Thus, we set out to

identify novel cyclic peptidomimetics for binding to pre-miR-155 and investigate
their ability to antagonize miR-155 associated biological activity.
4.2 Results and discussion
4.2.1 Screen for pre-miR-155 binder
Oligomers of γ-substituted-N-acylated-N-aminoethylamino acids (γ-AA) were
used earlier to construct one-bead−one-compound (OBOC) combinatorial
libraries comprised of linear, γ-AA derived, peptides (γ-AApeptides). Members of
these libraries were found to be remarkably stable and to have great functional
diversity.153 A new strategy for preparing cyclic γ-AApeptide libraries, employing
a thioether-bridge approach, was recently reported.148 In collaboration with Dr.
Jianfeng Cai’s research group at University of South Florida, we screened a
library of novel macrocyclic γ-AApeptides against pre-miR-155. Compound 58
was identified as the hit.
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Figure 4.1 Fluorescence polarization of fluorescein (a) and 58-Fl (b) in the
presence of different concentrations of pre-miR-155. The error bars represent the
standard error of the mean (N = 3).. 20
4.2.2 Binding affinity of the hit to pre-miR-155
Binding of 58 to pre-miR-155 was first demonstrated using the fluorescence
polarization (FP) assay. A fluorescein-tagged derivative 58-Fl (synthesized by
the Cai research group) was prepared for use in the FP assay. The results show
that

the

fluorescence

polarization

of

58-Fl

increases

with

increasing

concentrations of pre-miR-155 (Figure 4.1). The data arising from the saturation
binding curve was used to determine that the binding affinity (Kd) of 58-Fl toward
pre-miR-155 is 515 (±186) nM. In contrast, fluorescein alone does not have an
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effect on the FP of pre-miR-155. These results indicate that the hit compound 58
binds to pre-miR-155.
Binding of 58 to pre-miR-155 was further demonstrated by using an
electrophoretic mobility shift assay. The electrophoretic mobility of

32

P-labeled

pre-miR-155, prepared by using in vitro transcription, in the presence of various
concentrations of 58 was determined by using a non-denatured polyacrylamide
gel and phosphor imaging. The observation of a clear reduction in the mobility of
pre-miR-155 on the gel with increasing concentrations of 58 (Figure 4.2) shows
that a complex between 58 and pre-miR-155 is formed.

Figure 4.2 The electrophoretic mobility of pre-miR-155 in the presence of
compound 58.. 21
4.2.3 In vitro Dicer blocking activity
Next we assessed whether binding of 58 to pre-miR-155 disrupts the
interaction between pre-miR-155 and Dicer, and it inhibits miR-155 maturation
(Credit to Umesh Bhattarai). As part of an in vitro pre-miR-155 processing
assay,137

32

P-labeled pre-miR-155 was incubated with recombinant human Dicer

in the absence or presence of 58. The Dicer processing reaction was then
monitored by using denaturing polyacrylamide gel electrophoresis along with
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phosphor imaging. In the absence of 58, Dicer efficiently cleaves pre-miR-155 to
form mature miR-155. However, in the presence of increasing concentrations of
58, Dicer-mediated miR-155 processing is disrupted (Figure 4.3), as reflected in
a 63% reduction in the level of mature miR-155 formation caused by 30 µM of 58.
This result demonstrates that 58 effectively blocks Dicer processing of pre-miR155 in vitro.

Figure 4.3 (a) Representative image from electrophoresis analysis of Dicermediated pre-miR-155 cleavage in the presence of varing concentrations of 58.
(b) Densitometric quantitative analysis of miR-155 for images in panel a arising
from three independent assays. Error bars represent the standard error of mean
(N = 3). Figure courtesy of Umesh Bhattarai.. 22

4.2.4 MiR-155 inhibition in cell
High cell permeability is a prerequisite for the activities of miRNA inhibitors in
cells. To evaluate the cellular uptake efficiency of the macrocyclic peptidomimetic
58, HEK293T and MCF-7 cells were treated with 58-Fl. The results of fluorescent
microscopy showed that after incubation for 7 h very strong fluorescence
emanates from both cell lines (Figure 4.4), indicating that 58 is readily cell
permeable.
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Figure 4.4 Fluorescence microscope imaging of HEK293T and MCF-7 cells
treated with DMSO or 58-Fl. 23
The inhibitory effect of 58 on miR-155 maturation in cells was assessed next.
HEK293T cells were transiently transfected with a plasmid encoding pre-miR-155.
Mature miR-155 levels were then determined as a function of the concentration
of 58 using RT-qPCR. As the graph in Figure 4.5 a shows, 58 reduces the level
of miR-155 in a dose dependent manner, exemplified by a 70% reduction at 30
µM of 58. Thus, 58 inhibits the production of miR-155 in cells.

Figure 4.5 (a) Inhibition of miR-155 production by 58 (24 h treatment) in
HEK293T cells overexpressing miR-155. (b) 58 inhibits endogenous miR-155
formation after 96 h treatment of MCF-7 cells. The error bars represent the
standard error of the mean (N = 3).. 24
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We next tested if 58 inhibits endogenous miR-155 production in cells. Because
miR-155 is upregulated in many cancer cells, the breast cancer cell line MCF-7
was used in this study. We were aware that it might be difficult to downregulate
endogenous miR-155 through blocking its biogenesis because it has a very long
half-life.154 Despite this, treatment of MCF-7 cells with 58 (30 µM) for 96 h leads
to a 38% decrease in miR-155 level (Figure 4.5 b), a similar reduction to that
brought about by other small-molecule miRNA inhibitors.90, 113 Meanwhile, miR155 precursors were found to accumulate in the cells, indicating that the
reduction in miR-155 formation is indeed caused by blocking pre-miR-155
cleavage. The combined results demonstrate that 58 inhibits endogenous miR155 biogenesis in cancer cells by disrupting Dicer processing.

Figure 4.6 The selectivity of 58 in inhibiting miR-155 over other miRNAs in MCF7 cells. The error bars represent the standard error of the mean (N = 3).. 25
4.2.5 Selectivity of 58 to MiR-155 over other miRNAs
To assess whether the binding activity of 58 is selective toward miR-155, we
determined if changes in the levels of several other miRNAs in MCF-7 cells are
promoted by treatment with 58 for 96 h. As shown in Figure 4.6, in contrast to its
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significant effect on decreasing the miR-155 level, 58 displays little or no
inhibitory effects on other tested miRNAs, indicating good selectivity of 58.
4.2.6 58 upregulates miR-155 target protein FOXO3A
Owing to its activity and selectivity in inhibiting miR-155 in cells, the
macrocyclic peptidomimetic 58 serves as a model for a new family of small
molecules that have potential utility in the treatment of cancers and other miR155-associated diseases. To explore this proposal, initial experiments were
carried out with tumor suppressor gene FOXO3A, a direct target of miR-155155
whose loss in activity increases the resistance of cancer cells to apoptosis, which
results in cell-cycle progression.156 In line with expectations, we observed using
RT-qPCR (Figure 4.7 a) and immunoblotting (Figure 4.7 b and c) that inhibition of
miR-155 by 58 in MCF-7 cells leads to increases in the levels of FOXO3A mRNA
and protein.

Figure 4.7 (a) RT-qPCR analysis of mRNA and (b) Western blotting analysis of
protein levels of FOXO3A in MCF-7 cells either treated or not treated with 58. (c)
Densitometric quantitative analysis of FOXO3A as shown in panel b. Error bars
represent the standard error of mean (N = 3).. 26
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4.2.7 58 induces cancer cell apoptosis
To assess whether 58 induces cell apoptosis, MCF-7 cells were incubated
with 58 for 96 h and then stained with propidium iodide (PI) and fluoresceinlabeled annexin V. Flow cytometry analysis showed that 58 promotes an
increase in the population of cells undergoing both early apoptosis (Annexin+/PI-)
and late apoptosis (Annexin+/PI+) (Figure 4.8 a-c). The cell apoptosis rate is
increased by 12%, which is a similar level to that brought about by treatment with
an anti-miR-155 oligonucleotide (Figure 4.8 d).

Figure 4.8 Flow cytometry analysis of MCF-7 cell apoptosis under different
conditions. (a) Control; (b) 58 (30 µM); (c) anti-miR-155 (30 nM). (d) Quantitation
of cell apoptosis rate as in panel a, b and c. Error bars represent the standard
error of the mean (N = 3).. 27
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Characteristic morphological changes of apoptotic cells including cell
shrinkage, rounding and membrane blebbing were also observed to take place
using microscopy (Figure 4.9).157 These results demonstrate that 58 promotes
upregulation of miR-155 target gene and induces apoptosis.

Figure 4.9 Morphological changes of MCF-7 cells after 4 day treatment with
DMSO or 58. Arrows indicate the apoptotic cells showing blebbing.. 28

Figure 4.10 Viability analysis for MCF-7 cells treated with 58. The error bars
represent the standard error of the mean (N = 6).. 29
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4.2.8 58 inhibits cancer cell viability
Finally, because miR-155 inhibition reduces cancer cell proliferation,151 it was
anticipated that 58 would cause a decrease in the viability of MCF-7 cells. To test
the validity of this proposal, cell viability assays were conducted using 3-(4,5dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT). The observation of
a 70% reduction in the viability of MCF-7 cells after incubation with 58 (30 μM) for
96 h (Figure 4.10) demonstrates that this macrocyclic peptidomimetic strongly
inhibits cancer cell viability.
4.3 Summary
In summary, in the experiments described above, we designed and
synthesized a novel combinatorial macrocyclic γ-AApeptide library. A screen of
this library against pre-miR-155 led to identification of the new pre-miR-155
binder 58. Moreover, we found that 58 inhibits Dicer-mediated pre-miR-155
processing in vitro and in MCF-7 cells, and, consequently, that it induces
apoptosis and reduces growth of these cells. Because of their modular property
along with their high propensity for side chain alteration, macrocyclic
peptidomimetics should be amenable to systematic structural optimization to
obtain specific miRNA binding agents. We believe that 58 is a promising lead for
generating more potent miR-155 inhibitors that are designed to treat cancers and
other miR-155-associated diseases. This study also demonstrates that
macrocyclic peptidomimetics can serve as a new RNA targeting scaffold.
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4.4 Experiment details
4.4.1 In vitro Transcription of pre-miR-155
Pre-miR-155 was prepared by in vitro transcription.111 The sequence of premiR-155 was obtained from miRBase (http://www.mirbase.org/). The DNA
template used for making pre-miR-155 RNA was generated by PCR primer
extension. Briefly, forward primer:
5'GAAATTAATACGACTCACTATAGGCTGTTAATGCTAATCGTGATAGGGGTTT
TTGCCTCCAACTG-3’
and reverse primer:
5'-CTGTTAATGCTAATATGTAGGAGTCAGTTGGAGGCAAAAACCCCTA-3’
0.8 μM of each were subjected to primer extension using Taq polymerase
(Ambion) per the manufacture’s protocol. The extended dsDNA was purified with
NucleoSpin gel and PCR clean-up kit (Macherey-Nagel). The hybrid DNA
template with T7 promoter was used for in vitro transcription using T7
polymerase following manufacturer’s instructions (New England Biolabs). The
reaction mixture was treated with DNase to digest the template DNA and then
extracted with phenol/chloroform/isoamyl alcohol (25:24:1) (pH 6.7). The RNA
was finally precipitated by ethanol and resuspended in water for storage at 20 °C. Right before use, the RNA was allowed to refold as follows: RNA was
heated to 94 oC for 2 min and then cooled to 4 oC at a rate of 1 oC/s.
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4.4.2 Fluorescence polarization binding assay
The affinity of fluorescein (10 nM) or 58-Fl (10 nM) to pre-miR-155 was
determined using fluorescence polarization assay as described in 2.4.2.
4.4.3 Electrophoretic mobility shift assay
Electrophoretic mobility shift assay (EMSA) was used to study the binding of
58 to pre-miR-155.

32

P-labeled pre-miR-155 was prepared by in vitro

transcription as described above except that [alpha-P32] Uridine 5'-triphosphate
(UTP) (Perkinelmer) was used to take the place of regular UTP. A 10 µL of
binding mixture was made by incubating

32

P-labeled pre-miR-155 (1 µL, ̴20 ng)

with various concentrations of 58 in buffer (HEPES 24 mM, NaCl 200 mM, EDTA
0.04 mM, MgCl2 2.5 mM, pH 7.5) at 37 °C for 20 min. Gel loading buffer (10X,
Sucrose 40%, Xylene Cyanol 0.17%, Bromophenol Blue 0.17%) was then added.
The bound RNA was resolved from the free RNA using 12% non-denaturing
polyacrylamide gel at 4 °C and visualized by phosphor imaging.
4.4.4 Cell culture
HEK293T and MCF-7 cells were cultured in DMEM medium (Gibco) without
antibiotics, supplemented with 10% FBS and 2 mM GlutaMAX (Life Technologies)
at 37 °C in a humidified atmosphere containing 5% CO2.
4.4.5 Dicer enzyme expression
The Dicer enzyme was expressed as describe in 3.4.3.
4.4.6 Dicer-mediated pre-miR-155 cleavage assay
32

P-labeled pre-miR-155 was prepared as described in EMSA assay. A 10 µL

of the reaction mixture was made by incubating
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32

P-labeled pre-miR-155 (1 µL,

~20 ng) with Dicer enzyme (3 µL) and various concentrations of 58 in buffer
(HEPES 24 mM, NaCl 200 mM, EDTA 0.04 mM, MgCl2 2.5 mM, ATP 1 mM, pH
7.5) at 37 °C for 2.5 h. The reaction was stopped by boiling with equal volume of
Gel Loading Buffer II (ThermoFisher Scientific) for 5 min. The non-cleaved premiR-155 and the processed miR-155 were resolved by 18% denaturing
polyacrylamide gel. The gel was imaged with phosphor imager and analyzed by
quantity one software (Bio-rad).
4.4.7 Fluorescence microscope imaging
HEK293T or MCF-7 cells were plated into 24-well plates and grown overnight
to 50%. The cells were then treated with 58-Fl (5 µM) or DMSO (0.2% v/v) for 7 h.
After removing the medium, the cells were washed with PBS and imaged by
fluorescence microscope (Axio Observer, Zeiss) under the GFP channel.
4.4.8 MiR-155 inhibition in cell
HEK293T cell overexpressing miR-155 was used for evaluating the inhibition
activity of 58. MiR155 in pcDNA3.1 was a gift from Heidi Schwarzenbach
(Addgene plasmid # 78126).158 HEK293T cells were plated in 24-well plates (500
µL of medium per well) and grown overnight to 6
̴ 0% confluency. The cells were
transfected with the plasmid DNA (200 ng/well) using Lipo3000 transfection
reagent (Invitrogen) per the manufacture’s protocol. Briefly, DNA (200 ng/well),
P3000 reagent (1 µL/well) and Lipofectamine 3000 reagent (1 µL/well) were
incubated in 50 µL of Opti-MEM reduced serum medium (ThermoFisher)
containing appropriate amount of 58 at room temperature for 15 min. The mixture
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was then added into the cell cultural medium and the cells were harvested for
RNA extraction after 24 h incubation.
MCF-7 cell was used for studying the activity of 58 in inhibiting endogenous
miR-155 in cell. The cells were plated in 24-well plates (500 µL of medium per
well) and grown overnight to ̴ 60% confluency. The cells were then treated with
58 (30 µM), DMSO (0.2% v/v) or anti-miR-155 (30 nM, transfected as described
above) (Integrated DNA Technologies). The cell cultural medium was replaced
with fresh one containing the corresponding small molecule every 24 h. The cells
were harvested after 4-day incubation for the following RT-qPCR, Western
blotting, and flow cytometry analysis.
4.4.9 RNA extraction and RT-qPCR
Total RNA was extracted using miRNeasy Mini Kit (Qiagen) per the
manufacturer’s protocol. MiRNA reverse transcription reactions were completed
using a Taqman MicroRNA RT Kit (Applied Biosystems) per the manufacturer’s
protocol. Approximately 10 ng of total RNA was used for U6, miR-25, miR-29a,
miR-29b and miR-221, 300 ng was used for miR-155, miR-214 and miR-519d.
The qPCR was performed on 7900HT Fast Real-Time PCR System (Applied
Biosystems) using Taqman Universal PCR Master Mix (Applied Biosystems) and
Taqman miRNA assays (Applied Biosystems) per the manufacturer’s protocol.
0.5 µL of the RT product was used for a 10 µL qPCR reaction. The triplicate
threshold cycles (Ct) obtained for each treatment were used to determine the
level of miRNA normalized to U6 small nuclear RNA using the 2-∆∆Ct method.115
The results presented were based on three independent assays.
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The reverse transcription reaction for mRNA (FOXO3A and GAPDH) and miR155 precursors was completed with 300 ng of total RNA using High Capacity
cDNA Reverse Transcription Kit (Applied Biosystems) per the manufacturer’s
protocol. 0.5 µL of the reaction mixture was used for qPCR assay (10 µL) with
PowerUp SYBR Green Master Mix (Applied Biosystems) per the manufacturer’s
protocol. Following are the sequences of primers used for qPCR:
Target

Forward primer

Reverse primer

FOXO3A

5’-TGACACAGTCGGACCCCTTG-3’

5’-GTTCTGATTGACCAAACTTCCCT-3’

GAPDH

5’-GGTGGTCTCCTCTGACTTCAACA-3’

5’-GTTGCTGTAGCCAAATTCGTTGT-3’

miR-155 precursors

5’-CTGTTAATGCTAATCGTGATAGGG-3’

5’-TGTAGGAGTCAGTTGGAGGC-3’

The triplicate threshold cycles (Ct) obtained for each treatment were used to
determine the level of target RNA normalized to GAPDH mRNA using the 2-∆∆Ct
method.115 The results presented were based on three independent assays.
4.4.10 Western Blotting
Western blotting assays were carried out following 2.4.6. FOXO3A primary
antibody (Cell Signaling Technology, FoxO3a (D19A7) Rabbit mAb) and GAPDH
primary antibody (Cell Signaling Technology, GAPDH (D16H11) XP® Rabbit
mAb) were used.
4.4.11 Flow Cytometry Assay
MCF-7 cells were treated with different compounds as described above for 4
days. After washing with PBS twice, the cells were collected by trypsinizing and
centrifugation. The cells were then stained with a mixture of fluorescein-annexin
V and propidium iodide (PI) using an apoptosis kit (Invitrogen, eBioscience
Annexin V-FITC Apop Kit) per the manufacture’s protocol. Flow cytometry was
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performed using a BD Accuri C6 Plus flow cytometer (BD Biosciences). The
quantification data provided were based on three independent assays.
4.4.12 Cell viability assay
The effect of 58 on MCF-7 cell proliferation were tested by MTT assay (MTT =
3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide). MCF-7 cells were
seeded in 96-well plates and grown overnight to around 60% confluency. The
cells were then treated with appropriate amount of 58 or DMSO (0.2% v/v). The
cell cultural medium was replaced with fresh one containing corresponding
compound. After 4 day treatment, the medium was removed and 10 µL of MTT
stock solution (12 mM) was added to wells along with 100 µL of phenol free
DMEM. The cells were incubated at 37 oC for 4 h. The MTT containing medium
was replaced with 50 µL of DMSO. The solution was mixed thoroughly by
pipetting and incubated at 37 oC for 10 min. The absorbance at 540 nm was
recorded with a plate reader (SpectraMax i3X, Molecular Devices). The relative
viability of the cells was calculated based on 6 parallel tests by comparing to the
controls. The result presented was based on three independent assays.
Statistical analysis
Data are presented as the mean ± SEM of three independent experiments.
Student’s t-test for significance was carried out using Microsoft Excel 2010
software. *p < 0.03 verses control sample were considered significant.
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